drug_serial	drug_all_name	highest_phase	disease_condition	formula	target_name	target_id	tr_smiles	modulator_serial	mod_feature	cas_id	basic_patent	drugbank_id	pubmed_id	ref_title
ADR000001	CCD-1042, Ganaxolone(Prop INN; USAN)	Phase III	Infantile spasm (West syndrome); Epilepsy, focal seizures; Genetic epilepsy disorders; Fragile X syndrome; Postpartum depression; Stress, post-traumatic; Epilepsy, status epilepticus; Epileptic encephalopathy, early infantile	C22H36O2	Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit alpha-3;Gamma-aminobutyric acid receptor subunit alpha-4;Gamma-aminobutyric acid receptor subunit alpha-5;Gamma-aminobutyric acid receptor subunit alpha-6	ASD01140000_3;ASD01140000_12;ASD01140000_13;ASD01140000_14;ASD01140000_15;ASD01140000_16	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C	ASD01140224	Activator;Activator;Activator;Activator;Activator;Activator	38398-32-2	GB 1380248; US 2007141161; US 2007148252; US 2015335659; US 2017182061; US 2018071315; US 2018296487; US 2018344708; US 3953429; US 5319115; WO 1993003732; WO 1993005786; WO 1995021617; WO 2006010085; WO 2007062266; WO 2008066899; WO 2011019821; WO 2016127170; WO 2017066626; WO 2018031748	DB05087	17199022	Ganaxolone.
ADR000002	CX717	Preclinical	Alzheimer's disease	C14H17NO3	Glutamate receptor 1;Glutamate receptor 2;Glutamate receptor 3;Glutamate receptor 4	ASD03930000_1;ASD01230000_1;ASD04920000_2;ASD12990000_1	O=C(N1CCCCC1)c1ccc2OCCOc2c1	ASD03930089	Activator;Activator;Activator;Activator	191744-13-5	WO 1998011892; WO 1998050036; WO 2008025148; WO 2010054336	DB05047	16104830	Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates.
ADR000003	Drotaverine;Drotaverin;Drotin;INN	Approved	Irritable bowel syndrome	C24H31NO4	Voltage-dependent L-type calcium channel subunit alpha-1C	ASD07150000_1		ASD07150007	Inhibitor	14009-24-6		DB06751	12163106	Drotaverine interacts with the L-type Ca(2+) channel in pregnant rat uterine membranes.
ADR000004	Lorazepam	Approved	Anxiety disorder	C15H10Cl2N2O2	Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit beta-2;Gamma-aminobutyric acid receptor subunit beta-3;Gamma-aminobutyric acid receptor subunit delta;Gamma-aminobutyric acid receptor subunit gamma-2	ASD01140000_3;ASD01140000_2;ASD01140000_10;ASD01140000_11;ASD01140000_1		ASD13350001	Activator;Activator;Activator;Activator;Activator	846-49-1		DB00186	10565838	Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation.
ADR000005	Carglumic Acid	Approved	Acute hyperammonaemia	C6H10N2O5	Carbamoyl-phosphate synthase [ammonia], mitochondrial	ASD07260000_1		ASD07260004	Activator	1188-38-1		DB06775	21941437	Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency.
ADR000006	Flurazepam	Approved	Insomnia	C21H23ClFN3O	Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit beta-2;Gamma-aminobutyric acid receptor subunit beta-3;Gamma-aminobutyric acid receptor subunit delta;Gamma-aminobutyric acid receptor subunit gamma-2	ASD01140000_3;ASD01140000_2;ASD01140000_10;ASD01140000_11;ASD01140000_1		ASD01140278	Activator;Activator;Activator;Activator;Activator	17617-23-1		DB00690	21447642	Different residues in the GABAA receptor benzodiazepine binding pocket mediate benzodiazepine efficacy and binding.
ADR000007	Ketazolam	Approved	Anxiety disorder	C20H17ClN2O3	Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit beta-2;Gamma-aminobutyric acid receptor subunit beta-3;Gamma-aminobutyric acid receptor subunit delta;Gamma-aminobutyric acid receptor subunit gamma-2	ASD01140000_3;ASD01140000_2;ASD01140000_10;ASD01140000_11;ASD01140000_1		ASD01140752	Activator;Activator;Activator;Activator;Activator	27223-35-4		DB01587		
ADR000008	Trametinib	Approved	Melanoma	C26H23FIN5O4	Dual specificity mitogen-activated protein kinase kinase 1;Dual specificity mitogen-activated protein kinase kinase 2	ASD01940000_1;ASD01950000_1		ASD01941033	Inhibitor;Inhibitor	871700-17-3		DB08911	21245089	GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
ADR000009	Cinacalcet	Approved	Hyperparathyroidism	C22H22F3N	Extracellular calcium-sensing receptor	ASD00460000_1		ASD00460003	Activator	226256-56-0	US20070259964	DB01012		
ADR000010	Ticagrelor	Approved	Stroke;Acute coronary syndrome undergoing percutaneous coronary intervention;	C23H28F2N6O4S	P2Y purinoceptor 12	ASD13170000_1		ASD13170002	Inhibitor	274693-27-5	US20130165696	DB08816		
ADR000011	Clonazepam	Approved	Epilepsy	C15H10ClN3O3	Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit beta-2;Gamma-aminobutyric acid receptor subunit beta-3;Gamma-aminobutyric acid receptor subunit delta;Gamma-aminobutyric acid receptor subunit gamma-2	ASD01140000_3;ASD01140000_2;ASD01140000_10;ASD01140000_11;ASD01140000_1		ASD01140147	Activator;Activator;Activator;Activator;Activator	1622-61-3	US3116203	DB01068		
ADR000012	ADX10059	Phase II	Reflux, Gastroesophageal;Migraines		Metabotropic glutamate receptor 5	ASD01910000_1			Inhibitor		US20170275265	DB05070		
ADR000013	Sirolimus	Approved	immunosuppressive 	C51H79NO13	Peptidyl-prolyl cis-trans isomerase FKBP1A 	ASD12310000_1		ASD05723001	Inhibitor	53123-88-9	US20080167335	DB00877		
ADR000014	Enasidenib	Approved	acute myeloid leukemia	C19H17F6N7O	Isocitrate dehydrogenase [NADP], mitochondrial 	ASD01720000_11		ASD01720154	Inhibitor	1446502-11-9		DB13874	29184081	Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
ADR000015	Rilpivirine	Approved	Others	C22H18N6	HIV-1 reverse transcriptase	ASD13680000_2		ASD02560066	Inhibitor	500287-72-9	US5914331	DB08864		
ADR000016	Rifapentine	Approved	Others	C47H64N4O12	DNA-directed RNA polymerase subunit beta 	ASD03670000_4		ASD03670007	Inhibitor	61379-65-5		DB01201	16096056	Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins.
ADR000017	Cyclothiazide, Anhydron; Doburil	Approved	Hypertension	C14H16ClN3O4S2	Glutamate receptor 2 	ASD01230000_2	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C2CC3CC2C=C3)cc1Cl |c:21|	ASD01230043	Activator	2259-96-3	WO 2005007106; WO 2010054336	DB00606	7529311	Cyclothiazide acts at a site on the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor complex that does not recognize competitive or noncompetitive AMPA receptor antagonists.
ADR000018	Piracetam	Approved	Others	C6H10N2O2	Glutamate receptor 3 	ASD04920000_1		ASD04920001	Activator	7491-74-9		DB09210	20163115	Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors.
ADR000019	maraviroc	Approved	Others	C29H41F2N5O	C-C chemokine receptor type 5	ASD00600000_2		ASD00600010	Inhibitor	376348-65-1		DB04835	21118814	New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
ADR000020	Ivermectin	Approved	Others	C95H146O28	Gamma-aminobutyric acid type B receptor;Neuronal acetylcholine receptor subunit alpha-7;Glycine receptor subunit alpha-3	ASD01150000_1;ASD13620000_1;ASD03090000_1		ASD01150592	Activator;Activator;Activator	70288-86-7		DB00602	9463487	Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor.
ADR000021	Cobimetinib	Approved	Others	C21H21F3IN3O2	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASEKINASE 1	ASD01940000_1		ASD01941075	Inhibitor	934660-93-2	US7803839	DB05239		
ADR000023	BNC-210	Phase II	Agitation	C17H23N3O3	Alpha7 nicotinic acetylcholine receptor	ASD03090000_1		ASD03091919	Inhibitor					
ADR000024	mavoglurant	Phase II	Fragile X syndrome	C19H23NO3	Metabotropic glutamate receptor 5	ASD01910000_1		ASD01916286	Inhibitor	543906-09-8	US20130331568	DB13004		
ADR000025	ADX-48621, Dipraglurant(Prop INN)	Phase II	Parkinson's disease levodopa-induced dyskinesia	C16H12FN3	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1	ASD01914228	Inhibitor	872363-17-2	WO 2005123703; WO 2013139941; WO 2013186311;US8101637	DB12733		
ADR000026	Basimglurant	Phase II	Fragile X syndrome	C18H13ClFN3	Metabotropic glutamate receptor 5	ASD01910000_1		ASD01910221	Inhibitor	802906-73-6		DB11833	25565255	Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.
ADR000027	HTL-0014242; HTL-14242	Phase I	Neurological disorders; Psychiatric disorders	C16H8ClFN4	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(nc1)-c1cc(ncn1)-c1cc(Cl)cc(c1)C#N	ASD01918084	Inhibitor	1644645-32-8	WO 2015008073		26225459	Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).
ADR000028	Vercirnon	Phase III	Inflammatory bowel disease	C22H21ClN2O4S	C-C chemokine receptor type 9	ASD16580000_1		ASD16580001	Inhibitor	698394-73-9		DB15250	27926729	Intracellular allosteric antagonism of the CCR9 receptor.
ADR000029	Avacopan	Phase III	ANCA-Associated Vasculitis	C33H35F4N3O2	C5a anaphylatoxin chemotactic receptor 1 	ASD11780000_1		ASD03160012	Inhibitor	1346623-17-3		DB15011	29867214	Orthosteric and allosteric action of the C5a receptor antagonists.
ADR000030	SHP099	Phase I	cancer	C16H19Cl2N5	Tyrosine-protein phosphatase non-receptor type 11	ASD09200000_1		ASD09200001	Inhibitor	1801747-42-1			27347692	Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
ADR000031	BPN14770	Phase II	Alzheimer's disease,Fragile X Syndrome	C19H14ClF3N4O	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	ASD02190000_1		ASD02190027	Inhibitor	1606975-12-5	US2015119362	DB14790		
ADR000032	BIND-2206; MK-2206; NSC-749607	Phase II	Leukemia, acute myeloid; Neuroendocrine cancer; Cancer, biliary; Cancer, liver (hepatocellular carcinoma); Cancer, nasopharynx; Cancer, breast; Cancer, prostate; Cancer, lung (non-small cell) (NSCLC); Lymphoma; Cancer, solid tumor; Cancer, gastroesophageal junction; Cancer, endometrium; Cancer, kidney (renal cell carcinoma); Melanoma; Cancer, colorectal; Cancer, fallopian tube; Cancer, pancreas metastatic; Cancer, peritoneum; Cancer, ovary (serous); Cancer, stomach (adenocarcinoma)	C25H21N5O	RAC-alpha serine/threonine-protein kinase 	ASD03240000_1	NC1(CCC1)c1ccc(cc1)-c1nc2C=CN3C(=O)NN=C3c2cc1-c1ccccc1 |c:16,22|	ASD00060026	Inhibitor	1032350-13-2	CN 106822904; CN 108187052; US 2013116274; WO 2006135627; WO 2008070016; WO 2008070041; WO 2010101734; WO 2010138377; WO 2012015741; WO 2013009535; WO 2014047398; WO 2015094928; WO 2015097667; WO 2015142605; WO 2016109665; WO 2016209688; WO 2017037578; WO 2017109778			
ADR000033	Alvocidib	Phase II	cancer	C21H20ClNO5	Cyclin-dependent kinase 2 	ASD04590000_1		ASD01320080	Inhibitor	146426-40-6		DB03496	10924512	Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site.
ADR000034	filibuvir	Phase II	Hepatitis C	C29H37N5O3	RNA-directed RNA polymerase	ASD13070000_1		ASD09990001	Inhibitor	877130-28-4		DB11878	19209845	Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.
ADR000035	lomibuvir	Phase II	Hepatitis C	C25H35NO4S	RNA-directed RNA polymerase	ASD13070000_1		ASD09990003	Inhibitor	1026785-55-6	US2013273003	DB11954		
ADR000036	BMS-929075	Phase I	Hepatitis C (HCV)	C31H24F2N4O3	RNA-directed RNA polymerase	ASD13070000_1		ASD14560001	Inhibitor	1217338-97-0	WO 2010030592	DB14950	28430437	Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.
ADR000037	Mitapivat	Phase II	Thalassaemia	C24H26N4O3S	Pyruvate kinase isozymes M1/M2	ASD02500000_2		ASD02500326	Inhibitor	1260075-17-9				
ADR000038	ABL-001; ABL-001-NX; L1F3R18W77 (UNII code), Asciminib(USAN; Rec INN)	Phase III	 Chronic Myelogenous Leukemia	C20H18ClF2N5O3	Tyrosine-protein kinase ABL1	ASD03320000_1	O[C@@H]1CCN(C1)c1ncc(cc1-c1ccn[nH]1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1	ASD03320068	Inhibitor	1492952-76-7	WO 2013171639; WO 2018060843	DB12597	28329763	The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
ADR000039	VM-902A	Phase II	Pain, chronic		High affinity nerve growth factor receptor	ASD07480000_1		ASD07480051	Inhibitor					
ADR000040	GS-0976; ND-630; NDI-010976; NDI-630, Firsocostat(Prop INN)	Phase II	Non-alcoholic steatohepatitis; Obesity; Diabetes	C28H31N3O8S	Acetyl-CoA carboxylase 1;Acetyl-CoA carboxylase 2	ASD13150000_1;ASD13160000_1	COc1ccccc1[C@H](CN1c2sc(c(C)c2C(=O)N(C1=O)C(C)(C)C(O)=O)-c1ncco1)OC1CCOCC1	ASD00430003	Inhibitor;Inhibitor	1434635-54-7 	CN 107629069; WO 2013071169; WO 2016112305; WO 2017151816; WO 2018161022; WO 2018183193; WO 2018183342; WO 2018193007		26976583	Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
ADR000041	Efaproxiral	Phase III	Metastatic Cancers	C20H23NO4	Hemoglobin subunit alpha 	ASD03910000_1		ASD03910095	Regulator	131179-95-8		DB08486	1995897	Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
ADR000042	MYK-461; SAR-439152, Mavacamten(Rec INN)	Phase III	Obstructive Hypertrophic Cardiomyopathy	C15H19N3O2	Myosin-7	ASD08190000_2	CC(C)N1C(=O)NC(N[C@@H](C)c2ccccc2)=CC1=O |c:17|	ASD08190002	Activator	1642288-47-8	US 2016030428; US 2017281626; US 2018311242; WO 2014205223	DB14921	26912705	A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.
ADR000043	AGI-006; STX-209, (R)-(-)-Baclofen; Arbaclofen(Prop INN; USAN); D-Baclofen; l-Baclofen, Ontinua ER	Preclinical	Autism spectrum disorders; Delayed gastric emptying (gastroparesis); Fragile X syndrome; Dyspepsia; Spasticity; Gastroesophageal reflux disease (GERD)	C10H12ClNO2	Gamma-aminobutyric acid type B receptor	ASD01150000_1	NC[C@H](CC(O)=O)c1ccc(Cl)cc1	ASD01150002	Activator	1134-47-0; 69308-37-8	US 2015342956; US 2016243067; US 2016243072; US 2016263043; US 2017216236; US 2017340570; US 2017340592; US 2017354625; US 2018000813; US 2018200214; US 2018200215; WO 1994025016; WO 2005025559; WO 2008066750; WO 2009153889; WO 2016132217; WO 2016132218; WO 2016132220; WO 2016132233; WO 2016195679; WO 2016195723			
ADR000044	Lactoquinomycin; Lactoquinomycin A; Medermycin	Preclinical	Infection, bacterial; Cancer		RAC-alpha serine/threonine-protein kinase	ASD03240000_1	C[C@H]1O[C@H](C[C@H]([C@@H]1O)N(C)C)c1ccc2C(=O)C3=C([C@@H](C)O[C@@H]4CC(=O)O[C@H]34)C(=O)c2c1O |t:18|		Inhibitor	60227-09-0; 100100-36-5 (deleted CAS)	WO 2007127218			
ADR000045	Hispidulin; Hispiduline	Preclinical	Ischemia, cerebral; Asthma; Psychiatric Disorders; Liver diseases; Cancer	C16H12O6	Gamma-aminobutyric acid receptor subunit alpha-6;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_16;ASD01140000_10;ASD01140000_1	COc1c(O)cc2OC(=CC(=O)c2c1O)c1ccc(O)cc1 |c:8|	ASD01140493	Activator;Activator;Activator	1447-88-7	CN 102151281; JP 1999180867; KR 2018096163; US 2012029066; WO 1987002981			
ADR000046	RSR-13, Efaproxiral sodium(Rec INNM; USAN), Efaproxyn; Revaproxyn	Phase II	Cancer, breast metastatic; Surgery, arterial coronary; Stroke; Cancer, cervix; Myocardial infarction; Chronic heart failure; Cancer, lung (non-small cell) (NSCLC); Glioma; Angina pectoris, stable	C20H22NNaO4	Hemoglobin	ASD03910000_1	[Na+].Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C([O-])=O)cc2)c1	ASD03910145	Inhibitor	170787-99-2; 131179-95-8 (free acid)	US 5432191; US 5525630; US 5648375; US 5677330; US 5705521; US 5731454; US 5827888; WO 1991012235; WO 1992020335; WO 1997034594; WO 1999048490; WO 1999049847; WO 2002068930; WO 2005102305; WO 2005102308; WO 2005102367; WO 2006017491; WO 2007123126; WO 2012075244			
ADR000047	PD-81723	Preclinical	Arrhythmia; Ischemia-reperfusion injury, renal	C14H12F3NOS	Adenosine receptor A1	ASD00170000_1	Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C	ASD00170026	Activator	132861-87-1	WO 2002009701			
ADR000048	IDRA-21	Preclinical	Cognitive disorders	C8H9ClN2O2S	Glutamate receptor 1	ASD03930000_1	CC1Nc2ccc(Cl)cc2S(=O)(=O)N1	ASD01230006	Activator	22503-72-6	US 5488049; WO 2002089848			
ADR000049	CR-2249; XY-2401, Neboglamine(Rec INN); Nebostinel(former INN)	Phase II	Depression; Cocaine dependency; Schizophrenia; Cognitive disorders; Substance abuse and dependence	C13H24N2O3	Glutamate receptor ionotropic, NMDA 2A	ASD02030000_4	CC1(C)CCC(CC1)NC(=O)[C@@H](N)CCC(O)=O	ASD02030757	Regulator	163000-63-3	WO 1994020454; WO 2005115373; WO 2007039869			
ADR000052	Org-21465	Phase I	Anesthesia	C27H43NO4	Gamma-aminobutyric acid-A receptor	ASD01140000_1	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOC(C)(C)C1	ASD01140531	Activator	167946-96-5	EP 0656365			
ADR000053	UC-781	Phase II	Infections, sexually transmitted; Infection, HIV	C17H18ClNO2S	Reverse Transcriptase/Ribonuclease H	ASD11920000_1	[#6]\[#6](-[#6])=[#6]\[#6]-[#8]-c1cc(-[#7]-[#6](=S)-c2ccoc2-[#6])ccc1Cl	ASD02560025	Inhibitor	178870-32-1	WO 1997019940; WO 1997045116			
ADR000054	S-18986	Phase I	Stroke; Cognitive disorders	C10H12N2O2S	Glutamate receptor 1	ASD03930000_1	O=S1(=O)N[C@H]2CCCN2c2ccccc12	ASD01230045	Activator	175340-20-2	CA 2153549; WO 2002089848			
ADR000055	CX-614	Preclinical	Cognitive disorders	C13H13NO4	Glutamate receptor 1	ASD03930000_1	O=C1N2CCCC2Oc2cc3OCCOc3cc12	ASD01230002	Activator		WO 1997036907; WO 2004062616; WO 2007124348; WO 2008025148; WO 2008027648; WO 2008118644			
ADR000056	SK&F-83959; SKF-83959	Preclinical	Parkinson's disease	C18H20ClNO2	Sigma non-opioid intracellular receptor 1	ASD02690000_1	CN1CCc2c(Cl)c(O)c(O)cc2C(C1)c1cccc(C)c1	ASD02690003	Regulator	80751-85-5	CN 106924735; US 4192872; WO 2012127871			
ADR000057	CX-691; Org-24448, Farampator(USAN; Rec INN)	Phase II	Depression; Schizophrenia	C12H13N3O2	Glutamate receptor 1	ASD03930000_1	O=C(N1CCCCC1)c1ccc2nonc2c1	ASD01230364	Activator	211735-76-1	WO 1998035950; WO 1999021422; WO 2004062616			
ADR000058		Preclinical	Parkinson's disease	C16H25ClN4O3S	D(2) dopamine receptor	ASD00990000_1	Cl.NC(=O)[C@H]1CS[C@@H]2CC[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12	ASD00990078	Regulator	221040-35-3				
ADR000059	ATx-201; Bay-2353; VU-0243604, Niclosamide, Niclocide; Tredemine; Yomesan	Approved	Infection, skin; Infection, viral; Infection, Zika virus; Impetigo; Infection, bacterial; Dermatitis, atopic; Rheumatoid arthritis; Cancer; Infection, helminthic	C13H8Cl2N2O4	Cytochrome P450 1A2;Neuropeptide Y receptor type 4	ASD13210000_1;ASD13410000_1	Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	ASD01870108	Inhibitor;Activator	50-65-7	CN 102432493; CN 102697760; CN 103864641; CN 104971059; CN 105030747; CN 105348069; CN 106176700; CN 106431949; CN 107184600; CN 108815147; CN 108815148; EP 3308780; US 2013150416; US 2015065526; US 2017056347; US 2018015153; US 2018280372; WO 2004006906; WO 2005060951; WO 2008021088; WO 2008155535; WO 2009032749; WO 2009118706; WO 2011035321; WO 2012051633; WO 2012068274; WO 2012143377; WO 2014023732; WO 2015065919; WO 2016038035; WO 2016201354; WO 2017048197; WO 2017050297; WO 2017127397; WO 2017157997; WO 2017210117; WO 2017223491; WO 2018128515; WO 2018128517; WO 2018133212; WO 2018173069			
ADR000060	SB-269652	Preclinical	Psychosis	C28H31N3O	D(2) dopamine receptor;D(3) dopamine receptor	ASD00990000_1;ASD04640000_1	O=C(N[C@H]1CC[C@H](CCN2CCc3ccc(cc3C2)C#N)CC1)c1cc2ccccc2[nH]1 |r,wU:3.2,wD:6.6,(4.41,.32,;4.87,-1.35,;3.53,-2.11,;2.2,-1.34,;.86,-2.09,;-.46,-1.32,;-.46,.22,;-1.79,.99,;-3.12,.22,;-4.45,1,;-4.45,2.55,;-5.79,3.33,;-7.12,2.55,;-8.46,3.31,;-9.79,2.54,;-9.79,1,;-8.45,.23,;-7.13,1,;-5.79,.23,;-11.13,.22,;-12.45,.98,;.87,.99,;2.21,.21,;6.41,-1.35,;7.31,-.11,;8.78,-.59,;10.11,.18,;11.44,-.57,;11.45,-2.13,;10.11,-2.89,;8.78,-2.13,;7.31,-2.6,)|	ASD00990086	Regulator;Regulator	215802-15-6	WO 1998050364			
ADR000063	T-62	Phase II	Pain, neuropathic; Neuralgia, postherpetic (PHN)	C15H14ClNOS	Adenosine receptor A1	ASD00170000_1	Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1	ASD00170401	Activator	40312-34-3	US 2009023799; US 6248774; WO 2008051760; WO 2008147939			
ADR000064	LY-404187	Preclinical	Depression; Cognitive disorders	C19H22N2O2S	Glutamate receptor 1	ASD03930000_1	CC(C)S(=O)(=O)NCC(C)c1ccc(cc1)-c1ccc(cc1)C#N	ASD03930208	Activator	211311-95-4	WO 1998033496; WO 2000006537			
ADR000065	LUF-5484	Preclinical	Others	C15H13Cl2NOS	Adenosine receptor A1	ASD00170000_1	Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)c(Cl)c1	ASD00170347	Activator	247206-93-5				
ADR000066	LY-487379	Preclinical	Anxiety disorder	C21H19F3N2O4S	Metabotropic glutamate receptor 2	ASD01880000_1	COc1ccccc1Oc1ccc(cc1)N(Cc1cccnc1)S(=O)(=O)CC(F)(F)F	ASD01880002	Activator	353231-17-1; 353229-59-1 (hydrochloride)	WO 2001056990			
ADR000067	CGP-7930	Preclinical	Epilepsy; Anxiety disorder; Depression; Smoking cessation therapy; Cocaine dependency; Pain, neuropathic; Psychosis; Alcoholism	C19H32O2	Gamma-aminobutyric acid type B receptor	ASD01150000_1	CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	ASD01150047	Activator		WO 2011113904			
ADR000068	LY-503430	Preclinical	Parkinson's disease	C20H25FN2O3S	Glutamate receptor 1	ASD03930000_1	CNC(=O)c1ccc(cc1)-c1ccc(cc1)[C@](C)(F)CNS(=O)(=O)C(C)C	ASD03930235	Activator	305445-26-5 (undefined stereoch.)	WO 2000066546; WO 2002032389			
ADR000069	GS-39783	Preclinical	Cocaine dependency	C15H23N5O2S	Gamma-aminobutyric acid type B receptor	ASD01150000_1	CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	ASD01150005	Activator					
ADR000071	VAS-203, 4-Amino-tetrahydro-L-biopterine; Ronopterin(Rec INN)	Phase III	Traumatic brain injury	C9H16N6O2	Nitric oxide synthase, endothelial	ASD03390000_2	[H][C@@]1(CNc2nc(N)nc(N)c2N1)[C@@H](O)[C@H](C)O |r|	ASD03390001	Inhibitor	206885-38-3 (free base)	WO 2004084906; WO 2006058669; WO 2015150294			
ADR000073	TP-003	Preclinical	Epilepsy; Anxiety disorder	C23H16F3N3O	Gamma-aminobutyric acid receptor subunit alpha-3;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_13;ASD01140000_10;ASD01140000_1	CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N	ASD01140210	Activator;Activator;Activator	628690-75-5	WO 2003099816; WO 2017129801			
ADR000074	BINA, Biphenyl-indanone A	Preclinical	Anxiety disorder; Cocaine dependency; Schizophrenia	C30H30O4	Metabotropic glutamate receptor 2	ASD01880000_1	Cc1c2C(=O)C(Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1	ASD01880092	Activator	866823-73-6	WO 2006015158			
ADR000075	ITPP; ITPP sodium salt; OXY-111-A; OXY-111A, Inositol Tripyrophosphate; myo-Inositol Trispyrophosphate	Phase I	Heart failure; Cancer	C6H7Na5O21P6	Hemoglobin	ASD03910000_1	[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]P1(=O)O[C@H]2[C@H](OP([O-])(=O)O1)[C@H]1OP([O-])(=O)OP([O-])(=O)O[C@@H]1[C@@H]1OP([O-])(=O)OP([O-])(=O)O[C@H]21	ASD03910146	Inhibitor	23103-35-7	US 2006106000; US 2006258626; US 2007135389; US 2012003161; US 2014142052; WO 2008082658; WO 2008134082; WO 2014143939			
ADR000076	NSC-216666; PNU-120596	Preclinical	Schizophrenia	C13H14ClN3O4	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	ASD03090012	Activator	501925-31-1	WO 2003093250; WO 2006067611; WO 2008028903			
ADR000077	RO-4491533	Preclinical	Depression; Cognitive disorders; Psychosis	C24H20F3N3O	Metabotropic glutamate receptor 2;Metabotropic glutamate receptor 3	ASD01880000_1;ASD05170000_1	Cc1cc(cc(C)n1)-c1cccc(c1)C1=Nc2cc(C)c(cc2NC(=O)C1)C(F)(F)F |t:16|	ASD01870250	Inhibitor;Inhibitor	579482-31-8	WO 2003066623; WO 2005014002			
ADR000079	KC-706	Phase II	Lipoprotein disorders; Cardiovascular Disorders; Pemphigus; Psoriasis; Rheumatoid arthritis		Mitogen-activated protein kinase 14	ASD03490000_1			Inhibitor					
ADR000080	AMN-082	Preclinical	Others	C28H30Cl2N2	Metabotropic glutamate receptor 7	ASD01920000_2	Cl.Cl.C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	ASD01920002	Activator	97075-46-2; 83027-13-8 (free base); 84199-10-0 (dimethanesulfonate)	GB 2093023; WO 2008131439; WO 2009132050; WO 2010074992			
ADR000081	S-70340; S-70340-1	Preclinical	Neurodegeneration; Cognitive disorders		Glutamate receptor 1	ASD03930000_1			Activator					
ADR000082	NS-1738	Preclinical	Neurodegeneration; Cognitive disorders; Psychosis	C14H9Cl2F3N2O2	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	Oc1ccc(Cl)cc1NC(=O)Nc1cc(ccc1Cl)C(F)(F)F	ASD03090011	Activator	501684-93-1	WO 2005092843			
ADR000083	PLG	Preclinical	Psychosis; Parkinson's disease	C13H23N3O4	D(2) dopamine receptor	ASD00990000_1	CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)NCC(O)=O	ASD00990095	Regulator					
ADR000084	PAOPA	Preclinical	Psychosis; Parkinson's disease	C11H18N4O3	D(2) dopamine receptor	ASD00990000_1	NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O	ASD00990098	Regulator		WO 2012027825			
ADR000085	SH-053-2'F-S-CH3	Preclinical	Anxiety disorder; Convulsions; Alcoholism	C23H18FN3O2	Gamma-aminobutyric acid receptor subunit alpha-2;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_12;ASD01140000_10;ASD01140000_1	CCOC(=O)c1ncn-2c1[C@H](C)N=C(c1ccccc1F)c1cc(ccc-21)C#C |t:13|	ASD01140043	Activator;Activator;Activator		US 2010261711; WO 2006004945			
ADR000086	SH-053-2'F-R-CH3	Preclinical	Anxiety disorder; Convulsions; Alcoholism	C23H18FN3O2	Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_3;ASD01140000_10;ASD01140000_1	CCOC(=O)c1ncn-2c1[C@@H](C)N=C(c1ccccc1F)c1cc(ccc-21)C#C |t:13|	ASD01140042	Activator;Activator;Activator		US 2010261711; WO 2006004945			
ADR000088	LUF-6000	Preclinical	Inflammation	C22H20Cl2N4	Adenosine receptor A3	ASD00190000_1	Clc1ccc(Nc2nc3ccccc3c3nc([nH]c23)C2CCCCC2)cc1Cl	ASD00190016	Regulator	890087-21-5	WO 2007089507; WO 2014024195			
ADR000089	LY-2389575	Preclinical	Pain; Depression; Psychosis	C16H19BrCl2N4O3S	Metabotropic glutamate receptor 3	ASD05170000_1	CS(O)(=O)=O.Clc1ccc(CN[C@H]2CCN(C2)c2ncc(Br)cn2)c(Cl)c1	ASD05170002	Inhibitor		WO 2006044454			
ADR000090	BNC-210; IW-2143	Phase II	Depression; Agitation; Panic disorder; Anxiety, generalized; Stress, post-traumatic		Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1			Inhibitor					
ADR000092	2-261; UCI-2-261	Preclinical	Anxiety disorder; Pain, neuropathic	C20H20Cl2N2O2	Gamma-aminobutyric acid receptor subunit beta2;Gamma-aminobutyric acid receptor subunit beta3	ASD01140000_2;ASD01140000_10	CC[C@H](C)NC(=O)C(=C/Nc1ccc(Cl)cc1)\C(=O)c1ccccc1Cl	ASD01140494	Activator;Activator		WO 2005108347			
ADR000093	2-262	Preclinical	Anxiety disorder	C20H20Cl2N2O2	Gamma-aminobutyric acid receptor subunit beta2;Gamma-aminobutyric acid receptor subunit beta3	ASD01140000_2;ASD01140000_10	CC[C@@H](C)NC(=O)C(=C/Nc1ccc(Cl)cc1)\C(=O)c1ccccc1Cl	ASD01140602	Activator;Activator		WO 2005108347			
ADR000095	729327; GSK-729327	Phase I	Schizophrenia		Glutamate receptor 1	ASD03930000_1			Regulator					
ADR000096	JNJ-1930942	Preclinical	Cognitive disorders; Psychosis	C16H11F4N3OS	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	OCc1sc(Nc2ccc(F)c(c2)C(F)(F)F)nc1-c1ccncc1	ASD03090017	Activator		CN 102863435; WO 2007031440			
ADR000097	M-5MPEP	Preclinical	Cocaine dependency	C15H13NO	Metabotropic glutamate receptor 5	ASD01910000_1	COc1cccc(c1)C#Cc1ccc(C)cn1	ASD01910090	Inhibitor		WO 2007035823			
ADR000098	RMG-40083; XY-4083	Preclinical	Schizophrenia; Dementia, Alzheimer's type; Cognitive disorders		Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1			Activator					
ADR000099	ADX-63365	Preclinical	Schizophrenia; Mild cognitive impairment (MCI)		Metabotropic glutamate receptor 5	ASD01910000_1			Regulator					
ADR000100		Preclinical	Cognitive disorders	C9H11FN2O2S	Glutamate receptor 1	ASD03930000_1	CCN1CNS(=O)(=O)c2cc(F)ccc12	ASD01238023	Activator	945388-09-0	WO 2001040210			
ADR000101	MMPIP	Preclinical	Others	C19H15N3O3	Metabotropic glutamate receptor 7	ASD01920000_2	COc1ccc(cc1)C1=Cc2onc(c2C(=O)N1C)-c1ccncc1 |t:9|	ASD01920024	Inhibitor		WO 2002102807			
ADR000102	A-716096	Preclinical	Neurodegeneration; Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Psychosis	C14H13F2N3O3S	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	CN(C)C(=O)\N=C1/SC(C)=CN1c1ccc2OC(F)(F)Oc2c1 |c:9|	ASD03090819	Activator		WO 2008002956			
ADR000103	A-867744	Preclinical	Neurodegeneration; Cognitive disorders; Psychosis	C20H19ClN2O3S	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O	ASD03090018	Activator		WO 2008002974			
ADR000104	ML-108; VU-0152100; VU-152100	Preclinical	Schizophrenia	C18H17N3O3S	Muscarinic acetylcholine receptor M4	ASD01840000_1	COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1	ASD01840092	Regulator		WO 2016179351			
ADR000105	VU-0152099; VU-152099	Preclinical	Schizophrenia	C20H31NO	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc2OCOc2c1	ASD01840091	Regulator	612514-42-8				
ADR000106	ADX-71943	Preclinical	Incontinence, urinary; Pain, osteoarthritis; Inflammation; Gastroesophageal reflux disease (GERD)	C21H18FN5O5	Gamma-aminobutyric acid type B receptor	ASD01150000_1	COC1=NN(C(=O)N(Cc2ccc(C#N)c(OC)c2)C1=O)c1ccc(F)c(NC(C)=O)c1 |t:2|	ASD01150639	Activator		WO 2008056257			
ADR000108	A-969933; NS-9283	Preclinical	Pain; Cognitive disorders	C15H9N3O	Neuronal acetylcholine receptor subunit alpha-4;Neuronal acetylcholine receptor subunit beta-2	ASD03080000_1;ASD03080000_2	N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1	ASD03080083	Activator;Activator	913830-15-6	WO 2006114400; WO 2008028903; WO 2008073942; WO 2009148452			
ADR000109	VCP-171	Preclinical	Pain; Coronary artery disease; Hypertension	C18H12F3NOS	Adenosine receptor A1	ASD00170000_1	Nc1scc(c1C(=O)c1ccccc1)-c1cccc(c1)C(F)(F)F	ASD00170204	Activator		WO 2009049362			
ADR000110	CX-1632; S-47445, Tulrampator(Rec INN)	Phase II	Major depression; Dementia, Alzheimer's type	C20H17FN4O3	Glutamate receptor 1	ASD03930000_1	Fc1cccc(CCN2N=Nc3cc4C(=O)N(COc4cc3C2=O)C2CC2)c1 |c:9|	ASD01230384	Activator		WO 2008085506; WO 2015155451; WO 2016151265			
ADR000111		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Psychosis	C20H17FN4O3	Glutamate receptor 1	ASD03930000_1	Fc1cccc(CCN2N=Nc3cc4C(=O)N5CCCC5Oc4cc3C2=O)c1 |c:9|	ASD03930245	Activator		WO 2008085505; WO 2011130411			
ADR000112		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Psychosis	C16H16N8O3	Glutamate receptor 1	ASD03930000_1	C[C@H](Cn1ncnn1)N1N=Nc2cc3C(=O)N4CCCC4Oc3cc2C1=O |c:10|	ASD03930246	Activator		WO 2008085505; WO 2011130411			
ADR000113	CX-1739	Phase II	Depression; Attention deficit hyperactivity disorder (ADHD); Sleep apnea, central; Dementia, Alzheimer's type; Hypoventilation (respiratory depression)	C13H15N3O3	Glutamate receptor 1	ASD03930000_1	CN(C1CCOCC1)C(=O)c1ccc2nonc2c1	ASD03930247	Activator		CN 102030734; WO 2008143963; WO 2018009256			
ADR000114	TBPB	Preclinical	Psychosis	C25H32N4O	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1ccccc1CN1CCC(CC1)N1CCC(CC1)N1C(=O)Nc2ccccc12	ASD01810049	Activator	634616-95-8	WO 2003105781			
ADR000115	VU-10010	Preclinical	Psychosis	C17H16ClN3OS	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1	ASD01841075	Activator	633283-39-3	WO 2016179351			
ADR000116	BHF-177	Preclinical	Anxiety disorder; Substance abuse and dependence	C19H20F3N3	Gamma-aminobutyric acid type B receptor	ASD01150000_1	Cc1ncc(c(N[C@@H]2C[C@H]3CC[C@@H]2C3)n1)-c1ccc(cc1)C(F)(F)F	ASD01151048	Activator	917896-43-6	WO 2006136442			
ADR000117	AZD-8529	Phase II	Smoking cessation therapy; Schizophrenia	C24H24F3N5O3	Metabotropic glutamate receptor 2	ASD01880000_1	Cc1cc(cc2CN(Cc3ccc(OC(F)(F)F)cc3)C(=O)c12)-c1nc(CN2CCNCC2)no1	ASD01881511	Activator		WO 2008150233; WO 2010148074; WO 2011084098			
ADR000118	AZ-7325; AZD-7325	Phase I	Autism spectrum disorders; Anxiety disorder; Neurological Disorders; Fragile X syndrome	C19H19FN4O2	Gamma-aminobutyric acid receptor subunit alpha-3;Gamma-aminobutyric acid receptor subunit alpha-2	ASD01140000_13;ASD01140000_12	CCCNC(=O)c1nnc2c(cccc2c1N)-c1c(F)cccc1OC	ASD01140649	Activator;Activator		US 2007142328; US 2016199373; US 2018104244; WO 2008155573			
ADR000119	BPQCA	Preclinical	Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M1	ASD01810000_1			Regulator					
ADR000120	CF-602; LUF-6096	Preclinical	Myocardial infarction; Osteoarthritis; Erectile dysfunction	C22H21Cl2N3O	Adenosine receptor A3	ASD00190000_1	Clc1ccc(Nc2cc(NC(=O)C3CCCCC3)c3ccccc3n2)cc1Cl	ASD00191051	Regulator		WO 2010020981			
ADR000121		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Parkinson's disease; Huntington's disease	C16H16N14O2	Glutamate receptor 1	ASD03930000_1	C[C@H](Cn1ncnn1)N1N=Nc2cc3C(=O)N(N=Nc3cc2C1=O)[C@H](C)Cn1ncnn1 |c:10,18|	ASD03930248	Activator		WO 2009038752			
ADR000122		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Parkinson's disease; Huntington's disease	C15H14N10O2	Glutamate receptor 1	ASD03930000_1	C[C@H](Cn1ncnn1)N1N=Nc2cc3C(=O)N(N=Nc3cc2C1=O)C1CC1 |c:10,18|	ASD03930249	Activator		WO 2009038752			
ADR000123		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Parkinson's disease; Huntington's disease	C13H12N10O2	Glutamate receptor 1	ASD03930000_1	C[C@H](Cn1ncnn1)N1N=Nc2cc3C(=O)N(C)N=Nc3cc2C1=O |c:10,19|	ASD03930250	Activator		WO 2009038752			
ADR000124		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Parkinson's disease; Huntington's disease	C15H16N10O3	Glutamate receptor 1	ASD03930000_1	COCCN1N=Nc2cc3C(=O)N(N=Nc3cc2C1=O)[C@H](C)Cn1ncnn1 |c:5,13|	ASD03930251	Activator		WO 2009038752			
ADR000125		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Parkinson's disease; Huntington's disease	C16H15N9O2	Glutamate receptor 1	ASD03930000_1	C[C@H](Cn1ncnn1)N1C=Nc2cc3C(=O)N(N=Nc3cc2C1=O)C1CC1 |c:10,18|	ASD03930252	Activator		WO 2009038752			
ADR000126	RO-5126946	Preclinical	Dementia, Alzheimer's type	C19H21ClN2O4S	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	COc1ccc(Cl)cc1C(=O)N[C@H]1[C@H](c2ccc(cc2)S(N)(=O)=O)C1(C)C	ASD03090007	Activator		WO 2009043784			
ADR000127	PQCA	Preclinical	Dementia, Alzheimer's type	C27H25N5O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CC(CN2CCC(CC2)(C#N)c2ccccn2)=C2C=CC=CN2C1=O |c:24,26,t:3,22|	ASD01811040	Regulator		WO 2009051715			
ADR000128		Preclinical	Dementia, Alzheimer's type	C24H15F2N7O	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CC(CN2CCC(CC2)(C#N)c2ccccc2)=C2C=CC=CN2C1=O |c:24,26,t:3,22|	ASD01811032	Regulator		WO 2009051715			
ADR000129	ADX-71149; JNJ-40411813	Phase II	Epilepsy; Anxiety disorder; Schizophrenia	C20H25ClN2O	Metabotropic glutamate receptor 2	ASD01880000_1	CCCCN1C=CC(N2CCC(CC2)c2ccccc2)=C(Cl)C1=O |c:5,t:21|	ASD01883529	Activator		WO 2009033704; WO 2015110435			
ADR000130	A-988056	Preclinical	Cognitive disorders; Psychosis	C17H14F5N3O4S	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	OCC1=CN(\C(S1)=N\C(=O)N1CC[C@H](F)C1)c1ccc2OC(F)(F)C(F)(F)Oc2c1 |t:2|	ASD03090897	Activator		WO 2008002956			
ADR000131	(+)-TFMPIP; PF-4401090	Preclinical	Anxiety disorder; Psychosis	C21H22F4N4O	Metabotropic glutamate receptor 2	ASD01880000_1	C[C@@H]1CN(Cc2nc3ncccc3n2C)CC[C@@H]1c1ccc(OC(F)(F)F)cc1F |r|	ASD01882899	Activator		WO 2008012622			
ADR000132	A-966276	Preclinical	Cognitive disorders; Psychosis	C17H13F4N3O3S	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	CN(CC#C)C(=O)\N=C1/SC(C)=CN1c1ccc2OC(F)(F)C(F)(F)Oc2c1 |c:11|	ASD03090946	Activator		WO 2008002956			
ADR000133	ML-292; VU-0364770	Preclinical	Pain; Migraine; Anxiety disorder; Multiple sclerosis; Diabetes type 2; Parkinson's disease; Macular degeneration	C12H9ClN2O	Metabotropic glutamate receptor 4	ASD01900000_1	Clc1cccc(NC(=O)c2ccccn2)c1	ASD01903003	Activator		WO 2009010454			
ADR000134		Preclinical	Pain; Schizophrenia; Sleep disorder; Dementia, Alzheimer's type	C23H22N4O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CC(CN2CCC(CC2)c2nc3ccccc3[nH]2)=C2C=CC=CN2C1=O |c:26,28,t:3,24|	ASD01812105	Regulator		WO 2009102574			
ADR000135	MFZ-10-7	Preclinical	Pain; Anxiety disorder; Fragile X syndrome; Gastroesophageal reflux disease (GERD); Substance abuse and dependence	C15H13FN2	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1cccc(n1)C#Cc1cc(F)cc(c1)C#N	ASD01918159	Inhibitor					
ADR000136		Preclinical	Pain; Schizophrenia; Sleep disorder; Dementia, Alzheimer's type	C25H21N3O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CC(CN2CCc3ccccc3C2c2ccncc2)=C2C=CC=CN2C1=O |c:27,29,t:3,25|	ASD01811131	Regulator		WO 2009117283			
ADR000137		Preclinical	Pain; Schizophrenia; Sleep disorder; Dementia, Alzheimer's type	C20H17ClN2O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CC(CN2CCc3cc(Cl)ccc3C2)=C2C=CC=CN2C1=O |c:21,23,t:3,19|	ASD01812110	Regulator		WO 2009117283			
ADR000138		Preclinical	Pain; Anxiety disorder	C24H26ClN5OS	Metabotropic glutamate receptor 5	ASD01910000_1	Cl.CC(C)c1cccc(n1)-c1c(NC(=O)[C@@H]2C[C@H]2C)snc1-c1ccc2nn(C)cc2c1	ASD01918161	Inhibitor		WO 2009123855			
ADR000139		Preclinical	Schizophrenia	C23H20F2N4O2S	Muscarinic acetylcholine receptor M4;Histamine H3 receptor	ASD01840000_1;ASD12400000_1	Cc1cc(OCCc2ccncc2)nc2sc(C(=O)NCc3cc(F)ccc3F)c(N)c12	ASD01840228	Regulator;Regulator					
ADR000140		Preclinical	Schizophrenia	C23H20F2N4O2S	Muscarinic acetylcholine receptor M4;Histamine H3 receptor	ASD01840000_1;ASD12400000_1	Cc1cc(OCCc2ccncc2)nc2sc(C(=O)NCc3cccc(F)c3F)c(N)c12	ASD01840229	Regulator;Regulator					
ADR000141	VU-0152129	Preclinical	Schizophrenia	C23H22N4O3S	Muscarinic acetylcholine receptor M4;Histamine H3 receptor	ASD01840000_1;ASD12400000_1	COc1ccc(CNC(=O)c2sc3nc(OCc4ccncc4)cc(C)c3c2N)cc1	ASD01840230	Regulator;Regulator					
ADR000142	CX-1837	Preclinical	Cognitive disorders		Glutamate receptor 1	ASD03930000_1			Activator		WO 2009038752; WO 2012121971			
ADR000143		Preclinical	Schizophrenia; Cognitive disorders	C17H11F6N3O	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	FC(F)(F)c1cc2cc(CNC(=O)c3ccc(nc3)C(F)(F)F)ccc2[nH]1	ASD03092270	Activator		WO 2009127678			
ADR000144	BQCA	Preclinical	Dementia, Alzheimer's type	C18H15NO4	Muscarinic acetylcholine receptor M1	ASD01810000_1	COc1ccc(CN2C=C(C(O)=O)C(=O)c3ccccc23)cc1 |t:8|	ASD01810162	Regulator		WO 2007067489; WO 2007100366			
ADR000145	VU-0184670	Preclinical	Schizophrenia; Dementia, Alzheimer's type	C17H25N3O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	CCOC(=O)N1CCC(CC1)NCCNC(=O)c1ccccc1	ASD01817043	Regulator					
ADR000146	ML-071; VU-0357017	Preclinical	Schizophrenia; Dementia, Alzheimer's type	C18H27N3O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	CCOC(=O)N1CCC(CC1)NCCNC(=O)c1ccccc1C	ASD01810071	Regulator					
ADR000147	PEPA	Preclinical	Anxiety disorder	C16H16F2N2O4S2	Glutamate receptor 1	ASD03930000_1	NC(=O)COc1c(F)cc(SCCNS(=O)(=O)c2ccccc2)cc1F	ASD04920003	Activator		WO 2006034196; WO 2013177484			
ADR000148	D-159687	Preclinical	Cognitive disorders	C21H19ClN2O2	CAMP-specific 3',5'-cyclic phosphodiesterase 4D	ASD02190000_1	COc1ccc(Cc2ccc(NC(N)=O)cc2)cc1-c1cccc(Cl)c1	ASD02190003	Inhibitor		WO 2009067600			
ADR000149	D-159404	Preclinical	Cognitive disorders	C21H18ClFN2O2	CAMP-specific 3',5'-cyclic phosphodiesterase 4D	ASD02190000_1	COc1ccc(Cc2ccc(NC(N)=O)cc2)c(F)c1-c1cccc(Cl)c1	ASD02190002	Inhibitor		WO 2009067600			
ADR000150		Preclinical	Dementia, Alzheimer's type	C22H15FN2O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CN(Cc2ccc(cc2)-c2cccnc2)c2cccc(F)c2C1=O |t:3|	ASD01810206	Regulator		WO 2008002621			
ADR000151	VU-0365114	Preclinical	Stroke; Schizophrenia; Dementia, Alzheimer's type; Dementia, vascular; Parkinson's disease	C22H14F3NO3	Muscarinic acetylcholine receptor M5	ASD01850000_1	FC(F)(F)Oc1ccc2N(Cc3ccc(cc3)-c3ccccc3)C(=O)C(=O)c2c1	ASD01850073	Regulator					
ADR000152	VU-0400265	Preclinical	Stroke; Schizophrenia; Dementia, Alzheimer's type; Dementia, vascular; Parkinson's disease	C22H14F3NO4	Muscarinic acetylcholine receptor M5	ASD01850000_1	FC(F)(F)Oc1ccc2N(Cc3ccc(Oc4ccccc4)cc3)C(=O)C(=O)c2c1	ASD01810069	Regulator					
ADR000153		Preclinical	Anxiety disorder	C20H11F2N3O2S2	Metabotropic glutamate receptor 5	ASD01910000_1	Nc1cnc2sc(c(-c3cccc(F)c3)c2c1)S(=O)(=O)c1cc(F)cc(c1)C#N	ASD01915062	Inhibitor		US 2009326002; WO 2007072095; WO 2010001185			
ADR000154	LY-2607540; THIIC	Preclinical	Anxiety disorder; Depression	C24H24F3N3O4	Metabotropic glutamate receptor 2	ASD01880000_1	CC(C)C(=O)c1ccc(OCc2ccc(CNC(=O)c3cn(C)cn3)cc2)c(c1O)C(F)(F)F	ASD01881506	Activator		WO 2010009062			
ADR000155	OSPL-502	Preclinical	Cognitive disorders	C25H24N2O7	Glutamate receptor 1	ASD03930000_1	CC12CN(CC(C)(CN(C1)C(=O)c1ccc3OCOc3c1)C2=O)C(=O)c1ccc2OCOc2c1	ASD01230268	Activator		WO 2008054252; WO 2011006653			
ADR000156		Preclinical	Dementia, Alzheimer's type	C22H20N4O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CC(CN2CCN(CC2)c2ccc(cc2)C#N)=C2C=CC=CN2C1=O |c:24,26,t:3,22|	ASD01813923	Regulator		WO 2009094279			
ADR000157		Preclinical	Dementia, Alzheimer's type	C26H24N2O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	CN(C)Cc1cccc(c1)-c1ccc(CN2C=C(C(O)=O)C(=O)c3ccccc23)cc1 |t:17|	ASD01812357	Regulator		WO 2008002621			
ADR000158		Preclinical	Dementia, Alzheimer's type	C26H23FN2O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	CN(C)Cc1cccc(c1)-c1ccc(CN2C=C(C(O)=O)C(=O)c3cccc(F)c23)cc1 |t:17|	ASD01810204	Regulator		WO 2008002621			
ADR000159		Preclinical	Dementia, Alzheimer's type	C20H13F2N3O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CN(Cc2ccc(cc2)-n2cccn2)c2c(F)ccc(F)c2C1=O |t:3|	ASD01810125	Regulator		WO 2010019391			
ADR000160		Preclinical	Dementia, Alzheimer's type	C19H13F2NO5	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CN(Cc2ccc3OCCOc3c2)c2cccc(F)c2C1=O |t:3|	ASD01812369	Regulator		WO 2010047990			
ADR000161		Preclinical	Dementia, Alzheimer's type	C19H14FN3O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1ncc2cc(CN3C=C(C(O)=O)C(=O)c4c(F)cccc34)ccc12 |t:9|	ASD01814168	Regulator		WO 2010047990			
ADR000162		Preclinical	Dementia, Alzheimer's type	C21H21N3O4	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1cc(cn1)-c1ccc(CN2C=C(C(O)=O)C(=O)C3=C2CCCC3O)cc1 |c:20,t:13|	ASD01811112	Regulator		WO 2009102588			
ADR000163		Preclinical	Dementia, Alzheimer's type	C23H21NO4	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC1CCCC2=C1C(=O)C(=CN2Cc1ccc(cc1)-c1ccccc1)C(O)=O |c:5,10|	ASD01811093	Regulator		WO 2009102588			
ADR000164		Preclinical	Sleep disorder	C17H11ClF3N3	Metabotropic glutamate receptor 2	ASD01880000_1	FC(F)(F)Cc1cnc2c(Cl)c(ccn12)-c1cc(Cl)c2[nH]ccc2c1	ASD01882906	Activator		WO 2010060589			
ADR000165	MK-7622	Phase II	Pain; Schizophrenia; Sleep disorder; Dementia, Alzheimer's type	C26H26N2O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1ccc(Cc2cc3C(=O)N(C=Nc3c3ccccc23)[C@H]2CCCC[C@@H]2O)cn1 |c:12|	ASD01812379	Regulator		WO 2010059773; WO 2016144727; WO 2017058691			
ADR000166	JNJ-39393406; T930SOU82P (UNII code)	Phase II	Depression; Smoking cessation therapy; Schizophrenia	C19H18F2N6O3	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	CN(C)C(=O)CCn1nc(Nc2ccc3OC(F)(F)Oc3c2)nc1-c1ccncc1	ASD03090211	Activator		WO 2007118903			
ADR000167	UoS-12258	Phase I	Schizophrenia	C17H19FN2O2S	Glutamate receptor 1	ASD03930000_1	CC(C)S(=O)(=O)N[C@H]1Cc2ccc(cc2C1)-c1ccc(F)nc1	ASD01230028	Activator		US 2008194648; WO 2006015828			
ADR000168	ADX-68692	Preclinical	Endometriosis; Prostatic hyperplasia, benign		Follicle-stimulating hormone receptor	ASD04880000_1			Inhibitor					
ADR000169	rac-BHFF	Preclinical	Anxiety disorder; Depression; Alcoholism	C17H21F3O3	Gamma-aminobutyric acid type B receptor	ASD01150000_1	CC(C)(C)c1cc2c(OC(=O)C2(O)C(F)(F)F)c(c1)C(C)(C)C	ASD01151072	Activator		US 2007027204			
ADR000170		Preclinical	Schizophrenia; Dementia, Alzheimer's type; Inflammation	C23H24N2O2S	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	Cc1ccc(NC(=O)c2cc(c(s2)N2CCOCC2)-c2ccccc2)c(C)c1	ASD03093016	Activator					
ADR000171	AF-710B; Anavex 3-71	Preclinical	Dementia, frontotemporal; Dementia, Alzheimer's type; Parkinson's disease	C21H28N2OS	Muscarinic acetylcholine receptor M1	ASD01810000_1	CC1SC2(CN1C(=O)CCc1c[nH]c3ccccc13)CCN(C)CC2	ASD01812382	Modulator		WO 2010084499			
ADR000172		Preclinical	Impulse control disorder; Parkinson's disease	C12H11N3	Metabotropic glutamate receptor 4	ASD01900000_1	Nc1nccc(\C=C\c2ccccc2)n1	ASD01901001	Activator					
ADR000173	1063-20; NAB-14	Preclinical	Epilepsy; Cognitive disorders; Psychosis	C20H21N3O3	Glutamate receptor ionotropic, NMDA 2C;Glutamate receptor ionotropic, NMDA 2D	ASD10950000_1;ASD14430000_1	CCN(CC)C(=O)Oc1ccc(cc1)C(=O)Nc1cccc2cc[nH]c12	ASD02030674	Inhibitor;Inhibitor		WO 2010088408			
ADR000174	ADX-50938	Preclinical	Dementia, Alzheimer's type; Psychosis	C20H17F2N3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)-c1nc(no1)[C@H]1CCCN(C1)C(=O)c1ccc(F)nc1	ASD01918164	Activator		WO 2005044797; WO 2006123249			
ADR000175	522-054	Preclinical	Schizophrenia; Cognitive disorders	C21H15F2N5	Neuronal acetylcholine receptor subunit alpha-7;Gamma-aminobutyric acid-A receptor	ASD03090000_1;ASD01140000_1	CCn1ccc2cc(ccc12)-c1ccc2nnc(-c3cc(F)ccc3F)n2n1	ASD03092293	Activator;Regulator		WO 2010104843			
ADR000176		Preclinical	Smoking cessation therapy	C13H8N6	Neuronal acetylcholine receptor subunit alpha-4;Neuronal acetylcholine receptor subunit beta-2;Neuronal acetylcholine receptor subunit alpha-5	ASD03080000_1;ASD03080000_2;ASD13120000_1	N#Cc1cccc(c1)-n1nnc(n1)-c1cccnc1	ASD03080109	Activator;Activator;Activator		WO 2010106106			
ADR000177		Preclinical	Anxiety disorder; Depression; Psychosis	C21H17FN2	Metabotropic glutamate receptor 2	ASD01880000_1	Fc1ccc(Cn2c(Cc3ccccc3)nc3ccccc23)cc1	ASD01883837	Activator					
ADR000178		Preclinical	Dementia, Alzheimer's type	C25H18ClN7O	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1ccccc1C1(CCN(CC2=C3C=CC=CN3C(=O)C(=C2)C(O)=O)CC1)C#N |c:13,15,17,23|	ASD01811037	Regulator		WO 2009051715			
ADR000179		Preclinical	Dementia, Alzheimer's type	C25H24N6O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CC(CN2CCC(CC2)(C#N)c2cccnc2)=C2C=CC=CN2C1=O |c:24,26,t:3,22|	ASD01811041	Regulator		WO 2009051715			
ADR000180	OZP-002	Preclinical	Depression; Dementia, Alzheimer's type		Sigma non-opioid intracellular receptor 1	ASD02690000_1	CC1(C)COP(=O)(c2cccc(Cl)c2)C(C)(C)N1		Regulator		WO 2017191034			
ADR000181	BIIB-104; PF-04958242; PF-4958242	Phase II	Memory impairment; Schizophrenia; Hypoacusis, sensorineural	C18H20N2O4S2	Glutamate receptor 1	ASD03930000_1	CC(C)S(=O)(=O)N[C@H]1COC[C@H]1Oc1ccc(cc1)-c1ccc(s1)C#N	ASD01230383	Activator		WO 2010150192			
ADR000182	Compound A	Preclinical	Cognitive disorders; Psychosis		Metabotropic glutamate receptor 2	ASD01880000_1			Activator					
ADR000183	JNJ-40068782	Preclinical	Anxiety disorder; Depression; Sleep disorder; Cognitive disorders; Psychosis	C21H23N3O	Metabotropic glutamate receptor 2	ASD01880000_1	O=C1N(CC2CC2)C=CC(N2CCC(CC2)c2ccccc2)=C1C#N |c:8,24|	ASD01883008	Activator		WO 2008107479			
ADR000184		Preclinical	Dementia, Alzheimer's type	C21H14FNO3	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CN(Cc2ccc3ccccc3c2)c2cccc(F)c2C1=O |t:3|	ASD01812066	Regulator		WO 2010047990			
ADR000185		Preclinical	Epilepsy; Anxiety disorder; Mood disorder; Schizophrenia; Eating disorder; Cognitive disorders; Substance abuse and dependence	C25H20F4N4O	Metabotropic glutamate receptor 2	ASD01880000_1	Fc1cc(ccc1Oc1ccnc(c1)C1CC1)-c1ccn2c(CC3CC3)nnc2c1C(F)(F)F	ASD01885584	Activator		WO 2010130423			
ADR000186		Preclinical	Psychosis	C19H18F4N4	Metabotropic glutamate receptor 2	ASD01880000_1	FC(F)(F)Cc1nnc2c(Cl)c(ccn12)N1CCC(F)(CC1)c1ccccc1	ASD01883908	Activator		WO 2010130424			
ADR000187	JNJ-42153605	Preclinical	Epilepsy; Psychosis	C18H17F3N4	Metabotropic glutamate receptor 2	ASD01880000_1	FC(F)(F)c1c(ccn2c(CC3CC3)nnc12)N1CCC(CC1)c1ccccc1	ASD01883909	Activator		WO 2010130424			
ADR000188	Org-27569	Preclinical	Others	C24H28ClN3O	Cannabinoid receptor 1	ASD03330000_1	CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1	ASD03330003	Inhibitor					
ADR000189	CPPZ	Preclinical	Schizophrenia	C18H19ClFN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(N2CCN(CC2)C(=O)COCc2ccncc2)c(Cl)c1	ASD01915255	Activator		WO 2007087135			
ADR000190	VU-0409106	Preclinical	Autism spectrum disorders; Pain; Anxiety disorder; Fragile X syndrome; Parkinson's disease; Gastroesophageal reflux disease (GERD); Substance abuse and dependence	C15H11FN4O2S	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1csc(NC(=O)c2cc(F)cc(Oc3cncnc3)c2)n1	ASD01916227	Inhibitor		US 2011152299; WO 2011035209			
ADR000191	VU-0404251	Preclinical	Psychosis	C15H11F2N3O	Metabotropic glutamate receptor 5	ASD01910000_1	C[C@@H](NC(=O)c1ccc(OCc2cccc(F)c2)nc1)C(C)(C)C	ASD01913702	Activator		WO 2011035324			
ADR000192		Preclinical	Dementia, Alzheimer's type	C21H20BrN3O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CC(CN2CCN(CC2)c2ccc(Br)cc2)=C2C=CC=CN2C1=O |c:23,25,t:3,21|	ASD01813838	Regulator		WO 2009094279			
ADR000193		Preclinical	Dementia, Alzheimer's type	C22H20F3N3O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	OC(=O)C1=CC(CN2CCN(CC2)c2ccc(cc2)C(F)(F)F)=C2C=CC=CN2C1=O |c:26,28,t:3,24|	ASD01813778	Regulator		WO 2009094279			
ADR000194	PXT-001687	Preclinical	Parkinson's disease	C22H23ClN4O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cl.O\N=C1/C=C(Oc2ccc(OCCN3CCOCC3)cc12)c1cc2cccn2cn1 |c:3|	ASD01870458	Activator		WO 2011051478			
ADR000195	RO-4432717	Preclinical	Depression; Cognitive disorders	C23H18F3N3O	Metabotropic glutamate receptor 2;Metabotropic glutamate receptor 3	ASD01880000_1;ASD05170000_1	Cc1cc(ccn1)-c1cccc(c1)C1=Nc2cc(C)c(cc2NC(=O)C1)C(F)(F)F |t:15|	ASD01882831	Inhibitor;Inhibitor		WO 2003066623; WO 2005014002			
ADR000196	E-1R	Preclinical	Cognitive disorders	C13H16N2O2	Sigma non-opioid intracellular receptor 1	ASD02690000_1	C[C@H]1[C@H](CC(=O)N1CC(N)=O)c1ccccc1	ASD02690045	Regulator		WO 2011054888; WO 2017021881			
ADR000197	VU-0360172	Preclinical	Schizophrenia; Psychosis	C18H15FN2O	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1	ASD01916183	Activator					
ADR000198		Preclinical	Cognitive disorders; Psychosis	C18H16F5N3O2	Glutamate receptor 1	ASD03930000_1	Fc1cc(cc(F)c1CN1CCCC1=O)-n1nc(c2COCCc12)C(F)(F)F	ASD03930262	Activator		WO 2008053031			
ADR000199		Preclinical	Cognitive disorders; Psychosis	C18H18F3N3O2	Glutamate receptor 1	ASD03930000_1	FC(F)(F)c1nn(c2CCOCc12)-c1ccc(cc1)C(=O)N1CCCC1	ASD03930263	Activator		WO 2008053031			
ADR000200		Preclinical	Cognitive disorders; Psychosis	C18H18F3N3O3	Glutamate receptor 1	ASD03930000_1	FC(F)(F)c1nn(c2CCCCc12)-c1ccc(cc1)C(=O)N1CCOCC1	ASD03930264	Activator		WO 2008110566			
ADR000201		Preclinical	Cognitive disorders; Psychosis	C15H16F3N3O3S	Glutamate receptor 1	ASD03930000_1	CS(=O)(=O)NCc1ccc(cc1)-n1nc(c2CCCCc12)C(F)(F)F	ASD03930265	Activator		WO 2008110566			
ADR000203		Preclinical	Cocaine dependency	C27H24ClNO4	Metabotropic glutamate receptor 2	ASD01880000_1	OC(=O)c1cc(ccc1Cl)-c1cccc(COc2ccc3C(=O)N(Cc3c2)C2CCCC2)c1	ASD01883776	Activator		WO 2011116356			
ADR000204		Preclinical	Cocaine dependency	C26H22ClNO4S	Metabotropic glutamate receptor 2	ASD01880000_1	OC(=O)c1cc(ccc1Cl)-c1cccc(COc2ccc3C(=O)N(Sc3c2)C2CCCC2)c1	ASD01883801	Activator		WO 2011116356			
ADR000205		Preclinical	Inflammation; Cancer	C16H14ClN3S	Glucocorticoid Receptor	ASD01190000_1	Cl.NCc1ccc(cc1)-c1cn2c(n1)sc1ccccc21	ASD01190063	Inhibitor					
ADR000206		Preclinical	Pain; Sleep disorder; Dementia, Alzheimer's type; Psychosis	C23H24N2O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1ccc(cc1)C1CCN(CC2=C3C=CC=CN3C(=O)C(=C2)C(O)=O)CC1 |c:13,15,17,23|	ASD01812086	Regulator		WO 2009102574			
ADR000207	ML-169; VU-0405652	Preclinical	Dementia, Alzheimer's type	C21H17BrFN3O4S	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1cc(NC(=O)CS(=O)(=O)c2cn(Cc3cc(Br)ccc3F)c3ccccc23)no1	ASD01812048	Regulator		WO 2011163280			
ADR000208	JNJ-42659604	Preclinical	Schizophrenia	C14H16N2O2S	Metabotropic glutamate receptor 5	ASD01910000_1	CN1CCc2nc(COc3ccccc3)sc2C1=O	ASD01918231	Activator		WO 2011073339			
ADR000209		Preclinical	Cognitive disorders; Psychosis	C22H21ClN2O	Metabotropic glutamate receptor 5	ASD01910000_1	Cl.CC1(C)CCC2=Nc3cc(ccc3C(=O)N2C1)C#Cc1ccccn1 |t:5|	ASD01918239	Activator		WO 2011075699			
ADR000210	LSN-2814617	Preclinical	Schizophrenia; Sleep disorder	C18H20FN5O	Metabotropic glutamate receptor 5	ASD01910000_1	CC(C)(C)c1nnc2C[C@H](CCn12)c1nc(no1)-c1ccc(F)cc1	ASD01910893	Activator		WO 2011082010			
ADR000211	TQS	Preclinical	Cognitive disorders; Psychosis	C22H20N2O2S	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	NS(=O)(=O)c1ccc2NC(C3CC=CC3c2c1)c1cccc2ccccc12 |c:12|	ASD03090013	Activator		WO 2004098600			
ADR000212	VU-0418506	Preclinical	Parkinson's disease	C14H10ClFN2	Metabotropic glutamate receptor 4	ASD01900000_1	Fc1ccc(Nc2n[nH]c3cccnc23)cc1Cl	ASD01901059	Activator		WO 2011100607			
ADR000213		Preclinical	Psychosis	C19H16FN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1cccc(c1)-c1noc(n1)[C@@H]1CN(C(=O)C1)c1ccc(F)cc1	ASD01918255	Activator					
ADR000214		Preclinical	Psychosis	C18H13ClFN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)N1CC(CC1=O)c1nc(no1)-c1cccc(Cl)c1	ASD01918256	Activator					
ADR000215		Preclinical	Schizophrenia	C22H28N6O3	Metabotropic glutamate receptor 2	ASD01880000_1	CN1C(=O)N(CC(C)(C)C)c2ccc(nc12)N1C[C@@H]2CC[C@H]1CN2C(=O)c1ccon1	ASD01883929	Activator		WO 2011034741			
ADR000216	CMPPE	Preclinical	Epilepsy; Nutrition disorders	C20H23ClN4O	Gamma-aminobutyric acid type B receptor	ASD01150000_1	Cc1cc(N2CCCCC2CCO)n2nc(cc2n1)-c1ccc(Cl)cc1	ASD01150934	Activator					
ADR000217		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Psychosis	C16H16N8O3	Glutamate receptor 1	ASD03930000_1	C[C@H](Cn1ncnn1)N1N=Nc2cc3C(=O)N(COc3cc2C1=O)C1CC1 |c:10|	ASD03930271	Activator		WO 2008085505; WO 2011130411			
ADR000218		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Psychosis	C17H17N7O3	Glutamate receptor 1	ASD03930000_1	C[C@H](Cn1ncnn1)N1C=Nc2cc3C(=O)N4CCCC4Oc3cc2C1=O |c:10|	ASD03930272	Activator		WO 2008085505			
ADR000219	MRZ-8676	Preclinical	Pain; Anxiety disorder; Dyskinesia; Cognitive disorders	C19H17NO	Metabotropic glutamate receptor 5	ASD01910000_1	CC1(C)CCc2nc(ccc2C1=O)C#Cc1ccccc1	ASD01918029	Inhibitor		WO 2007023290			
ADR000220	AZT-2	Preclinical	Cognitive disorders; Psychosis		Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1			Activator					
ADR000221	ADX-88178	Preclinical	Depression; Cocaine dependency; Anxiety, generalized; Psychosis; Parkinson's disease	C13H13N5S	Metabotropic glutamate receptor 4	ASD01900000_1	Cc1sc(Nc2nccc(C)n2)nc1-c1cn[nH]c1	ASD01901249	Activator		WO 2010079239			
ADR000222		Preclinical	Pain; Schizophrenia; Sleep disorder; Dementia, Alzheimer's type	C28H30N4O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	COc1c(cc(Cc2ccc(nc2)-c2cnn(C)c2)c2ccccc12)C(=O)N[C@H]1CCCC[C@@H]1O	ASD01814564	Regulator		WO 2011149801			
ADR000223		Preclinical	Pain; Schizophrenia; Sleep disorder; Dementia, Alzheimer's type	C25H28N2O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	COc1c(cc(Cc2ccc(C)nc2)c2ccccc12)C(=O)N[C@H]1CCCC[C@@H]1O	ASD01814563	Regulator		WO 2011149801			
ADR000224		Preclinical	Pain; Schizophrenia; Sleep disorder; Dementia, Alzheimer's type	C27H28N4O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	COc1c(cc(Cc2ccc(nc2)-n2cccn2)c2ccccc12)C(=O)N[C@H]1CCCC[C@@H]1O	ASD01814566	Regulator		WO 2011149801			
ADR000225		Preclinical	Pain; Schizophrenia; Sleep disorder; Dementia, Alzheimer's type	C23H23ClN2O4	Muscarinic acetylcholine receptor M1	ASD01810000_1	COc1c(cc(Cc2ccc(Cl)nc2)c2ccccc12)C(=O)N[C@H]1CCOC[C@@H]1O	ASD01814569	Regulator		WO 2011149801			
ADR000226		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Parkinson's disease; Huntington's disease	C17H17N13O2	Glutamate receptor 1	ASD03930000_1	C[C@H](Cn1ncnn1)N1C=Nc2cc3C(=O)N(N=Nc3cc2C1=O)[C@H](C)Cn1ncnn1 |c:10,18|	ASD03930273	Activator		WO 2009038752			
ADR000227		Preclinical	Attention deficit hyperactivity disorder (ADHD); Cognitive disorders; Parkinson's disease; Huntington's disease	C14H13N9O2	Glutamate receptor 1	ASD03930000_1	C[C@H](Cn1ncnn1)N1C=Nc2cc3C(=O)N(C)N=Nc3cc2C1=O |c:10,19|	ASD03930274	Activator		WO 2009038752			
ADR000228	VU-000069	Preclinical	Schizophrenia	C20H19NO	Metabotropic glutamate receptor 5	ASD01910000_1	CCCN1CCc2cc(ccc2C1=O)C#Cc1ccccc1	ASD01910675	Activator		WO 2008151184			
ADR000230	LSN-2463359	Preclinical	Schizophrenia; Sleep disorder	C16H15N3O	Metabotropic glutamate receptor 5	ASD01910000_1	CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1	ASD01911115	Activator		KR 2016126146; WO 2013188465			
ADR000231	COR-628	Preclinical	Others	C16H23NO3S	Gamma-aminobutyric acid type B receptor	ASD01150000_1	CCc1c(C)sc(NC(=O)C2CCCCC2)c1C(=O)OC	ASD01150324	Activator					
ADR000232	COR-627	Preclinical	Inflammation, skin	C20H27NO3S	Cannabinoid receptor 2;Gamma-aminobutyric acid type B receptor	ASD11730000_1;ASD01150000_1	CCc1c(C)sc(NC(=O)C23CC4CC(CC(C4)C2)C3)c1C(=O)OC	ASD01150307	Activator;Activator					
ADR000233	XMetA; XOMA-159	Preclinical	Diabetes type 2; Hyperglycemia; Diabetes; Diabetes type 1		Insulin Receptor	ASD01650000_1			Activator		WO 2011038302; WO 2016141111			
ADR000234	JNJ-46778212; VU-0409551	Preclinical	Psychosis	C20H17FN2O3	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)C(=O)N1CCc2nc(COc3ccccc3)oc2C1	ASD01914337	Activator		WO 2012031024			
ADR000235	VU-0240382	Preclinical	Schizophrenia; Psychosis	C17H13NO	Metabotropic glutamate receptor 5	ASD01910000_1	O=C1NCCc2cc(ccc12)C#Cc1ccccc1	ASD01910638	Activator					
ADR000236	VU-0092273	Preclinical	Schizophrenia; Psychosis	C20H19NO2	Metabotropic glutamate receptor 5	ASD01910000_1	OC1CCN(CC1)C(=O)c1ccc(cc1)C#Cc1ccccc1	ASD01910815	Activator		WO 2008151184			
ADR000237	VU-0361747	Preclinical	Schizophrenia; Psychosis	C19H17FN2O2	Metabotropic glutamate receptor 5	ASD01910000_1	OC1CCN(CC1)C(=O)c1ccc(nc1)C#Cc1cccc(F)c1	ASD01916185	Activator					
ADR000238		Preclinical	Schizophrenia	C21H27N7O2S	Metabotropic glutamate receptor 2	ASD01880000_1	CN1C(=O)N(CC(C)(C)C)c2ccc(nc12)N1C[C@@H]2CC[C@H]1CN2C(=O)c1csnn1	ASD01883930	Activator		WO 2011034741			
ADR000239		Preclinical	Sleep disorder	C22H20FN3O2	Metabotropic glutamate receptor 2	ASD01880000_1	CCCCN1C=CC(=C(C#N)C1=O)c1ccc(Oc2ccnc(C)c2)c(F)c1 |c:5,t:7|	ASD01883031	Activator		WO 2007104783; WO 2008107480			
ADR000240		Preclinical	Sleep disorder	C23H22ClN3O2	Metabotropic glutamate receptor 2	ASD01880000_1	CCCCN1C=CC(=C(C#N)C1=O)c1ccc(Oc2ccc(C)nc2C)c(Cl)c1 |c:5,t:7|	ASD01884063	Activator		WO 2007104783; WO 2008107480			
ADR000241		Preclinical	Sleep disorder	C22H21N3O2	Metabotropic glutamate receptor 2	ASD01880000_1	CCCCN1C=CC(=C(C#N)C1=O)c1ccc(Oc2ccnc(C)c2)cc1 |c:5,t:7|	ASD01883044	Activator		WO 2007104783; WO 2008107480			
ADR000242	ADX-71441	Preclinical	Epilepsy; Anxiety disorder; Smoking cessation therapy; Cocaine dependency; Pain, osteoarthritis; Overactive bladder; Pain, visceral; Charcot-Marie-Tooth disease, type 1A; Bladder disorders; Spasticity; Cystitis, interstitial; Alcoholism; Autism; Irritable bowel syndrome; Substance abuse and dependence	C19H15ClF2N4O4	Gamma-aminobutyric acid type B receptor	ASD01150000_1	COC1=NN(C(=O)N(Cc2ccc(Cl)c(F)c2)C1=O)c1ccc(F)c(NC(C)=O)c1 |t:2|	ASD01150599	Activator		WO 2008056257			
ADR000243	AZ-12216052	Preclinical	Anxiety disorder	C19H22BrNOS	Metabotropic glutamate receptor 8	ASD05180000_1	CCC(C)c1ccc(NC(=O)CSCc2ccc(Br)cc2)cc1	ASD05183001	Activator					
ADR000244		Preclinical	Sleep disorder	C21H20Cl2F3N3O	Metabotropic glutamate receptor 2	ASD01880000_1	O[C@H]1CC[C@@H](CC1)Nc1ccc(c(Cl)c1)-c1ccn2c(CC(F)(F)F)cnc2c1Cl |r,wU:1.0,wD:4.7,(.8,-19.45,;2.13,-20.22,;3.46,-19.45,;4.8,-20.22,;4.8,-21.76,;3.46,-22.53,;2.13,-21.76,;6.13,-22.53,;7.46,-21.76,;8.79,-22.53,;10.13,-21.77,;10.13,-20.22,;8.79,-19.45,;8.79,-17.91,;7.46,-20.22,;11.46,-19.45,;11.46,-17.9,;12.8,-17.14,;14.12,-17.91,;15.59,-17.45,;15.59,-15.91,;16.92,-15.14,;16.92,-13.6,;18.26,-15.91,;18.26,-14.37,;16.51,-18.7,;15.62,-19.92,;14.12,-19.45,;12.8,-20.22,;12.8,-21.76,)|	ASD01883938	Activator		WO 2009062676			
ADR000245		Preclinical	Sleep disorder	C23H21ClF3N3O	Metabotropic glutamate receptor 2	ASD01880000_1	O[C@H]1CC[C@@H](CC1)n1ccc2cc(ccc12)-c1ccn2c(CC(F)(F)F)cnc2c1Cl |r,wU:1.0,wD:4.7,(3.95,-19.34,;3.95,-17.8,;2.62,-17.03,;2.62,-15.49,;3.95,-14.72,;5.29,-15.49,;5.29,-17.03,;3.95,-13.18,;3.07,-11.96,;3.99,-10.71,;5.45,-11.17,;6.78,-10.4,;8.12,-11.17,;8.12,-12.71,;6.78,-13.48,;5.45,-12.71,;9.45,-10.4,;9.45,-8.85,;10.79,-8.09,;12.11,-8.86,;13.58,-8.4,;13.58,-6.86,;14.91,-6.09,;14.91,-4.55,;16.24,-6.86,;16.24,-5.32,;14.5,-9.65,;13.61,-10.87,;12.11,-10.4,;10.78,-11.17,;10.78,-12.71,)|	ASD01883748	Activator		WO 2010060589			
ADR000246		Preclinical	Sleep disorder	C24H21F3N4O	Metabotropic glutamate receptor 2	ASD01880000_1	O[C@H]1CC[C@@H](CC1)n1ccc2cc(ccc12)-c1ccn2c(CC(F)(F)F)cnc2c1C#N |r,wU:1.0,wD:4.7,(3.71,-19.11,;3.71,-17.57,;2.37,-16.8,;2.37,-15.26,;3.71,-14.49,;5.04,-15.26,;5.04,-16.8,;3.71,-12.95,;2.82,-11.73,;3.74,-10.48,;5.21,-10.94,;6.54,-10.17,;7.87,-10.94,;7.87,-12.49,;6.53,-13.25,;5.21,-12.48,;9.21,-10.17,;9.21,-8.62,;10.54,-7.86,;11.87,-8.63,;13.33,-8.17,;13.33,-6.63,;14.67,-5.86,;14.67,-4.32,;16,-6.63,;16,-5.09,;14.25,-9.42,;13.37,-10.64,;11.87,-10.17,;10.54,-10.94,;10.54,-12.48,;10.54,-14.02,)|	ASD01883761	Activator		WO 2010060589			
ADR000247		Preclinical	Sleep disorder	C23H19F3N4O	Metabotropic glutamate receptor 2	ASD01880000_1	FC(F)(F)Cc1cnc2c(C#N)c(ccn12)-c1ccc2n(ccc2c1)C1CCOCC1	ASD01883751	Activator		WO 2010060589			
ADR000248	VU-0366058	Preclinical	Anxiety disorder; Substance abuse and dependence	C20H15ClN4O	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)-c1nc(Nc2nc3ccccc3o2)ncc1C#N	ASD01912012	Inhibitor					
ADR000249		Preclinical	Cognitive disorders	C12H11ClN2O3S	Glutamate receptor 1	ASD03930000_1	CC1Nc2c(cc(Cl)cc2S(=O)(=O)N1)-c1ccoc1	ASD01230036	Activator					
ADR000250		Preclinical	Cognitive disorders; Psychosis	C21H18F2N2O2	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	CCOc1ccc(cc1)-c1cnc(NC)c(c1)C(=O)c1ccc(F)c(F)c1	ASD03092740	Activator					
ADR000251	KK-84A	Preclinical	Smoking cessation therapy	C22H25F3N4O	Gamma-aminobutyric acid type B receptor	ASD01150000_1	FC(F)(F)c1ccc(cc1)-c1cnc(nc1NC1CCCCCC1)C(=O)NC1CC1	ASD01151078	Activator					
ADR000252	KK-92A-1	Preclinical	Smoking cessation therapy	C19H22F3N3O	Gamma-aminobutyric acid type B receptor	ASD01150000_1	OCc1ncc(-c2ccc(cc2)C(F)(F)F)c(NC2CCCCCC2)n1	ASD01151069	Activator					
ADR000253	KK-37	Preclinical	Smoking cessation therapy	C19H22F3N3	Gamma-aminobutyric acid type B receptor	ASD01150000_1	Cc1ncc(c(NC2CCCCCC2)n1)-c1ccc(cc1)C(F)(F)F	ASD01150033	Activator					
ADR000254		Preclinical	Cocaine dependency	C26H22ClNO3	Metabotropic glutamate receptor 2	ASD01880000_1	OC(=O)c1cc(ccc1Cl)-c1cccc(c1)-c1ccc2C(=O)N(Cc2c1)C1CCCC1	ASD01884809	Activator		WO 2011116356			
ADR000255		Preclinical	Cocaine dependency	C28H27NO5	Metabotropic glutamate receptor 2	ASD01880000_1	COc1ccc(cc1-c1cccc(COc2ccc3C(=O)N(Cc3c2)C2CCCC2)c1)C(O)=O	ASD01883788	Activator		WO 2011116356			
ADR000256		Preclinical	Anxiety disorder	C20H17F3N4O5	Gamma-aminobutyric acid type B receptor	ASD01150000_1	COC1=NN(C(=O)N(Cc2ccc(F)c(OC)c2F)C1=O)c1ccc(F)c(NC(C)=O)c1 |t:2|	ASD01150546	Activator		WO 2008056257			
ADR000257	[11C]JNJ-42491293	Phase I	Diagnostics	C22H23ClF2N4O	Metabotropic glutamate receptor 2	ASD01880000_1	[11CH3]Oc1c(F)ccc(F)c1C1CCN(CC1)c1ccn2c(CC3CC3)nnc2c1Cl	ASD01884116	Activator		WO 2012062752			
ADR000258		Preclinical	Diagnostics	C22H24ClFN4O	Metabotropic glutamate receptor 2	ASD01880000_1	[11CH3]Oc1ccc(F)cc1C1CCN(CC1)c1ccn2c(CC3CC3)nnc2c1Cl	ASD01884112	Activator		WO 2012062752			
ADR000259		Preclinical	Diagnostics	C22H23ClF2N4O	Metabotropic glutamate receptor 2	ASD01880000_1	[11CH3]Oc1cc(F)cc(F)c1C1CCN(CC1)c1ccn2c(CC3CC3)nnc2c1Cl	ASD01884118	Activator		WO 2012062752			
ADR000260		Preclinical	Diagnostics	C22H23ClF2N4O	Metabotropic glutamate receptor 2	ASD01880000_1	[11CH3]Oc1ccc(F)c(F)c1C1CCN(CC1)c1ccn2c(CC3CC3)nnc2c1Cl	ASD01884117	Activator		WO 2012062752			
ADR000261		Preclinical	Schizophrenia; Cognitive disorders	C22H15FN2O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1cccc(c1)[C@H]1OC(=O)N[C@@H]1c1cncc(c1)C#Cc1ccccc1	ASD01913059	Activator		WO 2012064603			
ADR000262	RO-15-4515	Preclinical	Others		Gamma-aminobutyric acid-A receptor	ASD01140000_1			Inhibitor					
ADR000263	ML-289; VU-0463597	Preclinical	Depression; Schizophrenia; Dementia, Alzheimer's type	C22H23NO3	Metabotropic glutamate receptor 3	ASD05170000_1	COc1ccc(cc1)C#Cc1ccc(cc1)C(=O)N1CCC[C@@H](CO)C1	ASD05170042	Inhibitor					
ADR000264	VU-0405372	Preclinical	Psychosis	C15H13FN2O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1cccc(COc2ccc3C(=O)NCCc3n2)c1	ASD01915467	Activator		WO 2012092530			
ADR000265		Preclinical	Dementia, Alzheimer's type	C27H19F2N5O	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1ccccc1N1N=C2C(=CN(Cc3ccc(cc3)-n3cccn3)c3c(F)ccc(F)c23)C1=O |c:9,11|	ASD01815889	Regulator		WO 2011049731			
ADR000266		Preclinical	Anxiety disorder	C15H6FN3	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1cc(cc(c1)C#Cc1cccc(n1)C#N)C#N	ASD01918334	Inhibitor					
ADR000267	ML-293; VU-0409524	Preclinical	Schizophrenia; Dementia, Alzheimer's type	C15H13N3O2S	Muscarinic acetylcholine receptor M4	ASD01840000_1	COc1ccc(C)c2sc(NC(=O)c3ccncc3)nc12	ASD01841038	Regulator					
ADR000268		Preclinical	Schizophrenia; Dementia, Alzheimer's type	C14H12N4O2S	Muscarinic acetylcholine receptor M4	ASD01840000_1	COc1ccc(C)c2sc(NC(=O)c3ccncn3)nc12	ASD01840232	Regulator					
ADR000269		Preclinical	Psychosis	C18H13ClFN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)N1CC(CC1=O)c1nc(no1)-c1cccc(Cl)c1	ASD01912158	Activator					
ADR000270	VU-0424238; VU-238	Preclinical	Anxiety disorder; Obsessive-compulsive disorder; Depression	C16H12FN5O2	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1cc(Oc2cncnc2)cc(n1)C(=O)Nc1ccc(F)cn1	ASD01910006	Inhibitor		WO 2012118563			
ADR000271		Preclinical	Anxiety disorder; Obsessive-compulsive disorder; Depression	C17H12F2N4O2	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1cc(Oc2cncc(F)c2)cc(n1)C(=O)Nc1ccc(F)cn1	ASD01910013	Inhibitor		WO 2012118563			
ADR000272	ADX-68938	Preclinical	Epilepsy; Anxiety disorder; Schizophrenia		Metabotropic glutamate receptor 2	ASD01880000_1			Activator					
ADR000273		Preclinical	Psychosis	C19H20FN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1cccc(c1)-c1noc(n1)C1CN(C1)C(=O)[C@H]1CC2CCC1C2	ASD01918341	Activator					
ADR000274		Preclinical	Psychosis	C18H18F3N3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1cccc(c1)-c1noc(n1)C1CN(C1)C(=O)C1CCC(F)(F)CC1	ASD01912486	Activator					
ADR000275		Preclinical	Psychosis	C18H18ClF2N3O2	Metabotropic glutamate receptor 5	ASD01910000_1	FC1(F)CCC(CC1)C(=O)N1CC(C1)c1nc(no1)-c1cccc(Cl)c1	ASD01915194	Activator					
ADR000276		Preclinical	Psychosis	C20H21F3N4	Metabotropic glutamate receptor 2	ASD01880000_1	CCc1nnc2c(c(ccn12)N1CCC(CC1)c1ccccc1)C(F)(F)F	ASD01884126	Activator		WO 2010130424			
ADR000277		Preclinical	Psychosis	C22H22ClF3N4	Metabotropic glutamate receptor 2	ASD01880000_1	FC(F)(F)C1(CCN(CC1)c1ccn2c(CC3CC3)nnc2c1Cl)c1ccccc1	ASD01884123	Activator		WO 2010130424			
ADR000278	GSK-2830371	Preclinical	Cancer	C23H29ClN4O2S	Protein phosphatase 1D	ASD13130000_1	Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1	ASD13130001	Inhibitor		WO 2012149102			
ADR000279	VU-0403602	Preclinical	Psychosis	C18H15FN2O	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1cccc(c1)C#Cc1ccc(nc1)C(=O)NC1CCC1	ASD01915536	Activator		WO 2013049255			
ADR000280	RZ-358; XMetD; XOMA-358	Phase II	Hypoglycemia; Hyperinsulinemic hypoglycemia		Insulin Receptor	ASD01650000_1			Inhibitor					
ADR000281		Preclinical	Dementia, Alzheimer's type	C30H32N4O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	O[C@H]1CCCC[C@@H]1N1Cc2c(cc(CN3CCC(CC3)(C#N)c3ccccn3)c3ccccc23)C1=O	ASD01811667	Regulator		WO 2012158475			
ADR000282		Preclinical	Dementia, Alzheimer's type	C31H34N4O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	CC1N([C@H]2CCCC[C@@H]2O)C(=O)c2cc(CN3CCC(CC3)(C#N)c3ccccn3)c3ccccc3c12	ASD01812168	Regulator		WO 2012158475			
ADR000283	VU-0456940	Preclinical	Dementia, Alzheimer's type; Psychosis	C24H20F2N6O4S	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1cc(NC(=O)CS(=O)(=O)c2cn(Cc3ccc(nc3)-c3cnn(C)c3)c3cc(F)cc(F)c23)no1	ASD01817061	Regulator		WO 2011163280			
ADR000284	VU-0400100	Preclinical	Cognitive disorders; Psychosis	C14H16ClF3N2O3S	Metabotropic glutamate receptor 5	ASD01910000_1	CS(=O)(=O)N(CC(=O)NCC1CC1)c1cc(ccc1Cl)C(F)(F)F	ASD01915176	Activator					
ADR000285	BNC-375	Preclinical	Dementia, Alzheimer's type		Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1			Activator					
ADR000286	ADX-71743	Preclinical	Anxiety disorder; Substance abuse and dependence	C17H19NO2	Metabotropic glutamate receptor 7	ASD01920000_2	CCc1nc2c(CC(CC2=O)c2ccc(C)cc2C)o1	ASD09940001	Inhibitor					
ADR000287	ML-253; VU-0448088	Preclinical	Psychosis	C17H16ClN3OS	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nc2sc(C(=O)NCc3ccncc3)c(N)c2c(C)c1Cl	ASD01840238	Regulator					
ADR000289		Preclinical	Infertility, female	C29H33N9O3	Follicle-stimulating hormone receptor	ASD04880000_1	Cc1ccccc1N1CCN(CC1)c1ccc(cc1NC(=O)c1coc(n1)C1CC1)C(=O)NCCCc1nnn[nH]1	ASD04881134	Activator		WO 2013012848			
ADR000290		Preclinical	Dementia, Alzheimer's type; Cognitive disorders	C27H29N5O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	O=C(NC1CCOCC1)C1=CC(CN2CCC(CC2)(C#N)c2ccccn2)=C2C=CC=CN2C1=O |c:31,33,t:10,29|	ASD01816713	Regulator		WO 2011062853			
ADR000291		Preclinical	Dementia, Alzheimer's type; Cognitive disorders	C30H33N5O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	O[C@H]1CCCC[C@@H]1NC(=O)C1=CC(CN2CCN(CC2)c2cc3ccccc3cn2)=C2C=CC=CN2C1=O |c:35,37,t:11,33|	ASD01816668	Regulator		WO 2011062853			
ADR000292		Preclinical	Anxiety disorder	C20H20ClN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Clc1cccc(c1)C1=NC[C@]2(CCC[C@@H](C2)NC(=O)c2ccccn2)O1 |t:8|	ASD01918384	Inhibitor					
ADR000293		Preclinical	Anxiety disorder; Parkinson's disease; Gastroesophageal reflux disease (GERD)	C21H22ClN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1cccc(n1)C(=O)N[C@H]1CCC[C@]2(CN=C(O2)c2cccc(Cl)c2)C1 |c:17|	ASD01918385	Inhibitor					
ADR000294		Preclinical	Pain; Sleep disorder	C18H12ClN3OS	Gamma-aminobutyric acid receptor subunit delta	ASD01140000_11	Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	ASD01140552	Activator		GB 2448808			
ADR000295	ML-273; VU-0424465	Preclinical	Psychosis	C19H19FN2O2	Metabotropic glutamate receptor 5	ASD01910000_1	C[C@@H](NC(=O)c1ccc(cn1)C#Cc1cccc(F)c1)C(C)(C)O	ASD01916184	Activator					
ADR000296		Preclinical	Pain	C14H14N4O	Metabotropic glutamate receptor 5	ASD01910000_1	N#Cc1ccc(COc2cc3CCCCn3n2)nc1	ASD01918388	Inhibitor					
ADR000297	BL-010362	Preclinical	Cognitive disorders		Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1			Activator					
ADR000298	BNC-2591	Preclinical	Cognitive disorders		Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1			Activator					
ADR000299	BNC-1881	Preclinical	Cognitive disorders		Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1			Activator					
ADR000300		Preclinical	Depression	C18H17FN4O	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1c(nn(C)c1-c1ccc(F)cc1)C(=O)Nc1cccc(C)n1	ASD01918392	Inhibitor					
ADR000301		Preclinical	Depression	C18H16F2N4O	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1c(nn(C)c1-c1ccc(F)c(F)c1)C(=O)Nc1cccc(C)n1	ASD01918393	Inhibitor					
ADR000302		Preclinical	Depression	C18H17FN4O	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1nc(C(=O)Nc2cccc(C)n2)c(C)n1-c1ccc(F)cc1	ASD01918394	Inhibitor					
ADR000303		Preclinical	Depression	C16H14ClN5O	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1nc(C(=O)Nc2ccnc(Cl)n2)c(C)n1-c1ccccc1	ASD01918395	Inhibitor					
ADR000305	TASP-0443294	Preclinical	Schizophrenia	C18H20F3N3O3	Metabotropic glutamate receptor 2	ASD01880000_1	Cc1c(nc2O[C@H](COc3ccc(cc3)C(C)(C)C(F)(F)F)Cn12)C(N)=O	ASD01881608	Activator		JP 2014214130; WO 2013062079			
ADR000307		Preclinical	Other neurological disorders	C17H19NO3S	Gamma-aminobutyric acid type B receptor	ASD01150000_1	CCc1c(C)sc(NC(=O)c2ccc(C)cc2)c1C(=O)OC	ASD01151082	Activator					
ADR000308	COR-659	Preclinical	Alcoholism; Other neurological disorders	C16H16ClNO3S	Cannabinoid receptor 1;Gamma-aminobutyric acid type B receptor	ASD03330000_1;ASD01150000_1	CCc1c(C)sc(NC(=O)c2ccc(Cl)cc2)c1C(=O)OC	ASD01151083	Activator;Activator					
ADR000309		Preclinical	Other neurological disorders	C20H25NO3S	Gamma-aminobutyric acid type B receptor	ASD01150000_1	CCc1c(C)sc(NC(=O)c2ccc(cc2)C(C)(C)C)c1C(=O)OC	ASD01151084	Activator					
ADR000310		Preclinical	Other neurological disorders	C17H16F3NO3S	Gamma-aminobutyric acid type B receptor	ASD01150000_1	CCc1c(C)sc(NC(=O)c2ccc(cc2)C(F)(F)F)c1C(=O)OC	ASD01151085	Activator					
ADR000311	SOMCL-668	Preclinical	Epilepsy; Depression	C17H19NO	Sigma non-opioid intracellular receptor 1	ASD02690000_1	CN1CCc2cc(O)ccc2C(C1)c1ccccc1	ASD02690035	Regulator		CN 102895233			
ADR000312		Preclinical	Psychosis	C18H15FN4O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(nc1)N1CCn2nc(COc3ccccc3)cc2C1=O	ASD01915510	Activator		WO 2012083224			
ADR000313	CYD-1-79; CYD-8-71	Preclinical	Anxiety disorder; Depression; Schizophrenia; Obesity; Eating disorder; Parkinson's disease; Substance abuse and dependence	C20H40N2O3	5-hydroxytryptamine receptor 2C	ASD00110000_1	CCCCCCCCCCC[C@@H]1CCN[C@@H](C1)C(=O)NC[C@H](O)CO |r|	ASD00110046	Regulator		WO 2013086266			
ADR000314	VU-0469650	Preclinical	Pain; Anxiety disorder; Psychosis	C22H29ClN4O	Metabotropic glutamate receptor 1	ASD01870000_1	Cl[H].[H][C@]12C[C@]3([H])C[C@]([H])(C1)C[C@](C2)(C3)C(=O)N1CCN(C[C@H]1C)c1cccnc1C#N	ASD01870460	Inhibitor					
ADR000315	ML-337; VU-0469942	Preclinical	Depression; Dementia, Alzheimer's type; Cognitive disorders; Psychosis	C21H20FNO3	Metabotropic glutamate receptor 3	ASD05170000_1	COc1ccc(cc1)C#Cc1ccc(C(=O)N2CCC[C@@H](O)C2)c(F)c1	ASD05170036	Inhibitor					
ADR000316	VU-0477950	Preclinical	Depression; Dementia, Alzheimer's type; Cognitive disorders; Psychosis	C21H17D3FNO3	Metabotropic glutamate receptor 3	ASD05170000_1	[2H]C([2H])([2H])Oc1ccc(cc1)C#Cc1ccc(C(=O)N2CCC[C@@H](O)C2)c(F)c1	ASD05170008	Inhibitor					
ADR000317		Preclinical	Psychosis	C19H19N5O3S	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)NC3CN(C3)C(=O)Oc3ccccc3)c(N)c2c1C	ASD01840159	Activator		WO 2013126856			
ADR000318	LSN-2535717	Preclinical	Anxiety disorder	C22H20F3N3O4	Metabotropic glutamate receptor 2	ASD01880000_1	CC(=O)c1ccc(OCc2ccc(CNC(=O)c3cn(C)cn3)cc2)c(c1O)C(F)(F)F	ASD01883982	Activator		WO 2010009062			
ADR000319	ML-375; S-VU-0478333; VU-0483253	Preclinical	Dementia, Alzheimer's type; Psychosis; Parkinson's disease; Substance abuse and dependence	C23H15ClF2N2O2	Muscarinic acetylcholine receptor M5	ASD01850000_1	Fc1ccc(cc1F)C(=O)N1CCN2C(=O)c3ccccc3[C@@]12c1ccc(Cl)cc1	ASD01850087	Regulator					
ADR000320	VU-0463841	Preclinical	Cocaine dependency	C13H8ClFN4O	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1cc(NC(=O)Nc2ccc(Cl)cn2)cc(c1)C#N	ASD01918467	Inhibitor					
ADR000321	AVL-3288; Anvylic-3288; UCI-4083	Phase I	Schizophrenia; Cognitive disorders	C19H15Cl2N3O2	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1		ASD03091138	Activator	917837-54-8				
ADR000322	LSN-2313136	Preclinical	Migraine	C22H19N5O4	Cysteinyl leukotriene receptor 1;Metabotropic glutamate receptor 2	ASD13200000_1;ASD01880000_1	CC(=O)c1ccc(OCc2ccc(Oc3cc(ccn3)-c3nnn[nH]3)cc2)c(C)c1O	ASD01883993	Inhibitor;Activator		WO 2006057860			
ADR000323	PAM-2	Preclinical	Depression; Dementia, Alzheimer's type	C14H8N4O3	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	Cc1ccc(NC(=O)\C=C\c2ccco2)cc1	ASD03091073	Activator		CN 102973548			
ADR000324	SUVN-I1305036	Preclinical	Dementia, Alzheimer's type; Cognitive disorders; Psychosis		Muscarinic acetylcholine receptor M1	ASD01810000_1			Regulator					
ADR000325	PF-06297470; PF-470	Preclinical	Parkinson's disease	C18H16N6O	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1ccncc1-c1nn(C)c2nc(OCc3ccccn3)cnc12	ASD01918030	Inhibitor					
ADR000326	TR-M-573	Preclinical	Anxiety disorder; Dyskinesia		Metabotropic glutamate receptor 5	ASD01910000_1			Inhibitor					
ADR000327	Lu-AF-58801	Preclinical	Dementia, Alzheimer's type; Psychosis	C19H21NO3	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	COc1ccc(cc1)[C@H](CO)NC(=O)[C@H]1C[C@@H]1c1ccccc1	ASD03092859	Activator					
ADR000328	CYD-6-16-2	Preclinical	Anxiety disorder; Depression; Schizophrenia; Obesity; Eating disorder; Parkinson's disease; Substance abuse and dependence	C21H26N2O3	5-hydroxytryptamine receptor 2C	ASD00110000_1	OC[C@H](NC(=O)[C@@H]1C[C@@H](CCN1)c1ccccc1)[C@@H](O)c1ccccc1	ASD00110041	Regulator		WO 2013086266			
ADR000329	GAT-107	Preclinical	Pain; Cognitive disorders; Psychosis	C18H17BrN2O2S	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	NS(=O)(=O)c1ccc2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |c:12|	ASD03091863	Activator					
ADR000331	VU-0467154; VU-467154	Preclinical	Cognitive disorders; Psychosis; Huntington's disease	C17H15F3N4O3S2	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)NCc3ccc(cc3)S(=O)(=O)C(F)(F)F)c(N)c2c1C	ASD01840018	Activator		WO 2013126856; WO 2016179351			
ADR000332	ML-254; VU-0430644	Preclinical	Psychosis	C18H15FN2O2	Cytochrome P450 1A2;Metabotropic glutamate receptor 5	ASD13210000_1;ASD01910000_1	CC1(COC1)NC(=O)c1ccc(cn1)C#Cc1cccc(F)c1	ASD01916330	Inhibitor;Activator		WO 2013049255			
ADR000333	VU-001	Preclinical	Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M1	ASD01810000_1			Regulator					
ADR000334		Preclinical	Pain; Sleep disorder; Dementia, Alzheimer's type; Psychosis	C29H29N3O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	COc1c(cc(Cc2ccc(nc2)-c2cccnc2)c2ccccc12)C(=O)N[C@H]1CCCC[C@@H]1O	ASD01814544	Regulator		WO 2011149801			
ADR000335	JNJ-2463; RYI-018; RYI-028, Namacizumab; Nimacimab	Phase I	Non-alcoholic steatohepatitis; Nephropathy, diabetic; Non-alcoholic fatty liver disease (NAFLD); Fibrosis; Metabolic Diseases		Cannabinoid receptor 1	ASD03330000_1			Inhibitor					
ADR000336		Preclinical	Schizophrenia	C22H25N3O2	Metabotropic glutamate receptor 2	ASD01880000_1	CCCCN1CCn2c(ccc2-c2ccc3CN(C4CC4)C(=O)c3c2)C1=O	ASD01884017	Activator		JP 2013189395			
ADR000337		Preclinical	Infertility, female	C31H37N5O5	Follicle-stimulating hormone receptor	ASD04880000_1	Cc1ccccc1N1CCN(CC1)c1ccc(cc1NC(=O)c1coc(n1)C1CC1)C(=O)N[C@@H]1CCC[C@@H](O)[C@H]1O	ASD04880034	Activator		WO 2013012848; WO 2013106409			
ADR000338	AP-267	Preclinical	Substance abuse and dependence		5-hydroxytryptamine receptor 2C	ASD00110000_1			Regulator					
ADR000339		Preclinical	Depression	C18H14FN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(nc1)-c1nc2CN(CCc2o1)C(=O)c1ccccc1	ASD01918503	Inhibitor		WO 2014065270			
ADR000340		Preclinical	Depression	C18H12ClF2N3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(nc1)-c1nc2CN(CCc2o1)C(=O)c1cc(F)cc(Cl)c1	ASD01918504	Inhibitor		WO 2014065270			
ADR000341	DSR-98776	Preclinical	Mood disorder	C18H13F2N3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(nc1)-c1nc2CN(CCc2o1)C(=O)c1cccc(F)c1	ASD01918506	Inhibitor		WO 2014065270			
ADR000342	ML-380; VU-0481443	Preclinical	Incontinence, urinary; Dementia, Alzheimer's type; Psychosis; Parkinson's disease	C23H25F3N4O3S	Muscarinic acetylcholine receptor M5	ASD01850000_1	CCN(Cc1ccccc1C(F)(F)F)C(=O)C1CCN(CC1)S(=O)(=O)c1ccc2[nH]ncc2c1	ASD01850070	Regulator					
ADR000343	ASN-51	Preclinical	Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M1	ASD01810000_1			Regulator					
ADR000344	ABP-700, Cyclopropyl-methoxycarbonyl metomidate	Phase II	Sleep disorder; Anesthesia	C17H18N2O4	Gamma-aminobutyric acid-A receptor	ASD01140000_1	COC(=O)C1(CC1)OC(=O)c1cncn1[C@H](C)c1ccccc1	ASD01140658	Activator		WO 2013106717; WO 2017127835			
ADR000345		Preclinical	Dementia, Alzheimer's type	C31H34N4O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1ccnc(c1)C1(CCN(Cc2cc3C(=O)N(Cc3c3ccccc23)[C@H]2CCCC[C@@H]2O)CC1)C#N	ASD01812188	Regulator		WO 2012158475			
ADR000346		Preclinical	Anxiety disorder	C18H21ClF6N2O4	Neuronal acetylcholine receptor subunit alpha-3;Neuronal acetylcholine receptor subunit beta-4;Neuronal acetylcholine receptor subunit beta-2;Neuronal acetylcholine receptor subunit alpha-7;5-hydroxytryptamine receptor 3A	ASD04170000_1;ASD04170000_2;ASD03080000_2;ASD03090000_1;ASD00120000_3	OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.[H][C@]12CCN(CC1)C[C@H]2NCc1ccccc1Cl |THB:23:22:19.20:16.17|	ASD00120008	Activator;Activator;Activator;Regulator;Inhibitor					
ADR000347	[11C]KALB-012; [11C]PXT-012253	Preclinical	Diagnostics		Metabotropic glutamate receptor 4	ASD01900000_1	[11CH3]Sc1cc(NC(=O)c2ccccn2)ccc1Cl		Activator					
ADR000348	RG-7342	Phase I	Schizophrenia		Metabotropic glutamate receptor 5	ASD01910000_1			Activator					
ADR000349	VU-0431316	Preclinical	Anxiety disorder	C14 H9 Cl N6 O2	Cytochrome P450 1A2;Metabotropic glutamate receptor 5	ASD13210000_1;ASD01910000_1	Clc1ccnc(c1)C(=O)Nc1cncc(Oc2cncnc2)n1		Inhibitor;Inhibitor		WO 2011035174			
ADR000350		Preclinical	Cognitive disorders; Psychosis	C20H17FN2O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)C1CCn2nc(COc3ccccc3)cc2C1=O	ASD01918516	Activator					
ADR000351	BMS-955829	Preclinical	Schizophrenia; Cognitive disorders	C22H14F2N2O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(F)c(c1)[C@H]1OC(=O)N[C@@H]1c1cncc(c1)C#Cc1ccccc1	ASD01917532	Activator		WO 2012064603			
ADR000352		Preclinical	Anxiety disorder	C19H11Cl2NO2S2	Metabotropic glutamate receptor 5	ASD01910000_1	Clc1ccc(cc1)-c1c(sc2ncccc12)S(=O)(=O)c1ccc(Cl)cc1	ASD01915094	Inhibitor		WO 2007072095			
ADR000353		Preclinical	Diabetes type 2		Free fatty acid receptor 1	ASD09380000_1	[Na+].COc1cc(c(F)cn1)-c1ccc(nc1)C1CCc2ccc(cc2O1)[C@@H]([C@H](C)C([O-])=O)C1CC1 |r|		Activator		WO 2014130608			
ADR000354	VU-0453595	Preclinical	Psychosis	C18H15FN4O	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1cc(cn1)-c1ccc(CN2Cc3ncccc3C2=O)c(F)c1	ASD01810667	Regulator		WO 2013106795			
ADR000355	BB-243	Preclinical	Pain; Cognitive disorders; Hypertension	C15H12O5	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	Oc1ccc(\C=C\C(=O)c2cc(O)ccc2O)c(O)c1	ASD03091403	Activator					
ADR000356		Preclinical	Anxiety disorder; Psychosis	C20H23ClN2O	Metabotropic glutamate receptor 2	ASD01880000_1	ClC1=C(C=CN(CC2CC2)C1=O)N1CCC(CC1)c1ccccc1 |c:3,t:1|	ASD01883528	Activator		WO 2009033704			
ADR000357		Preclinical	Anxiety disorder; Psychosis	C20H25ClN2O	Metabotropic glutamate receptor 2	ASD01880000_1	CC(C)CN1C=CC(N2CCC(CC2)c2ccccc2)=C(Cl)C1=O |c:5,t:21|	ASD01883546	Activator		WO 2009033704			
ADR000358	SAGE-689	Preclinical	Sedation; Epilepsy, status epilepticus		Gamma-aminobutyric acid-A receptor	ASD01140000_1			Activator					
ADR000360	Alloswitch-1; trans-Alloswitch-1	Preclinical	Pain	C19H15ClN4O2	Metabotropic glutamate receptor 5	ASD01910000_1	COc1cc(ccc1NC(=O)c1ccccc1Cl)\N=N\c1ccccn1	ASD01914905	Inhibitor		WO 2015044358			
ADR000361	S-812217; SAGE-217	Phase III	Depression; Bipolar disorder; Major depression; Insomnia; Tremor, essential; Rett syndrome; Dravet syndrome (severe myoclonic epilepsy of infancy); Parkinson's disease; Postpartum depression	C25H35N3O2	Gamma-aminobutyric acid-A receptor	ASD01140000_1	[H][C@@]12CC[C@H](C(=O)Cn3cc(cn3)C#N)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@](C)(O)CC[C@]12[H]	ASD01140495	Activator		WO 2014169833; WO 2018039378			
ADR000362		Preclinical	Obesity; Maple syrup urine disease; Diabetes	C9H4Cl2O2S	[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial	ASD10690000_1	OC(=O)c1sc2cc(Cl)ccc2c1Cl	ASD10690003	Inhibitor		WO 2018144700			
ADR000364	VU-0476212	Preclinical	Dementia, Alzheimer's type; Psychosis; Parkinson's disease	C23H28N4O3S	Muscarinic acetylcholine receptor M5	ASD01850000_1	CCN([C@H](C)c1ccccc1)C(=O)C1CCN(CC1)S(=O)(=O)c1ccc2[nH]ncc2c1	ASD01850136	Regulator					
ADR000365	VU-0478436	Preclinical	Schizophrenia; Dementia, Alzheimer's type	C23H16F2N4O	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1cc2c(cccc2n1)-c1cc(F)c(CN2C(=O)C=Nc3ccccc23)c(F)c1 |c:21|	ASD01814698	Activator		WO 2014179226			
ADR000366	SUVN-I1312004	Preclinical	Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M1	ASD01810000_1			Activator					
ADR000367	MARP-1	Preclinical	Cognitive disorders		Glutamate receptor 1	ASD03930000_1			Activator					
ADR000368	SGE-872	Preclinical	Epilepsy; Autism spectrum disorders	C27H37N3O2	Gamma-aminobutyric acid-A receptor	ASD01140000_1	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@](C)(O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)C(=O)Cn1cc2ccncc2n1	ASD01140662	Activator		WO 2014169832			
ADR000369	AVL-8168	Preclinical	Cognitive disorders		Neuronal acetylcholine receptor subunit alpha-7;Gamma-aminobutyric acid-A receptor	ASD03090000_1;ASD01140000_1			Activator;Regulator					
ADR000370	TASP-0433864	Preclinical	Psychosis	C18H23N3O3	Metabotropic glutamate receptor 2	ASD01880000_1	Cc1c(nc2O[C@H](COc3ccc(cc3)C(C)(C)C)Cn12)C(N)=O	ASD01880001	Activator		WO 2013062079			
ADR000371	BPN-14770; D-159797	Phase II	Cognitive disorders	C19H14ClF3N4O	CAMP-specific 3',5'-cyclic phosphodiesterase 4D	ASD02190000_1		ASD02190027	Inhibitor	1606975-12-5				
ADR000372	JNJ-55375515	Phase I	Cognitive disorders; Psychosis	C20H17F3N4O	Metabotropic glutamate receptor 2	ASD01880000_1	C[C@H]1CN(C(=O)c2c(cnn12)-c1ccnc(C)c1)c1ccc(cc1)C(F)(F)F	ASD01884040	Inhibitor		WO 2014195311			
ADR000373	LY-315402; LY-3154207	Phase II	Dementia, Parkinson	C24H29Cl2NO3	D(1A) dopamine receptor	ASD13110000_1	C[C@@H]1N([C@@H](CO)Cc2c(CCC(C)(C)O)cccc12)C(=O)Cc1c(Cl)cccc1Cl	ASD13110004	Activator		WO 2014193781; WO 2017070068			
ADR000374		Preclinical	Cognitive disorders	C10H11ClN2O2S	Glutamate receptor 1	ASD03930000_1	Clc1ccc2N(CNS(=O)(=O)c2c1)C1CC1	ASD01200248	Activator		WO 2010004139			
ADR000375	VU-0453379	Preclinical	Parkinson's disease	C26H34N4O2	Glucagon-like peptide 1 receptor	ASD01180000_1	CC(C)N1CCC[C@H]1CNC(=O)C1=CN(C2CCCC2)C(=O)c2c1c1ccccc1n2C |t:13|	ASD01180126	Activator					
ADR000377	SGE-516	Preclinical	Epilepsy	C23H35N3O2	Gamma-aminobutyric acid-A receptor	ASD01140000_1	[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@](C)(O)CC[C@]4([H])[C@@]3([H])CC[C@]12C)C(=O)Cn1nccn1	ASD01140664	Activator		WO 2013056181			
ADR000378	VU-6000181	Preclinical	Dementia, Alzheimer's type; Psychosis; Parkinson's disease	C25H19F3N2O3	Muscarinic acetylcholine receptor M5	ASD01850000_1	COc1ccc(cc1C)[C@]12N(CCN1C(=O)c1ccccc21)C(=O)c1cc(F)c(F)c(F)c1	ASD01850132	Regulator					
ADR000380		Preclinical	Extrapyramidal disorders; Anxiety disorder; Depression; Autism	C17H8FN5	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(nc1)-c1cc(ncn1)-c1cc(cc(c1)C#N)C#N	ASD01918528	Inhibitor		WO 2015008073			
ADR000381		Preclinical	Extrapyramidal disorders; Anxiety disorder; Depression; Autism	C16H9ClN4	Metabotropic glutamate receptor 5	ASD01910000_1	Clc1cc(cc(c1)-c1cc(ncn1)-c1ccccn1)C#N	ASD01918529	Inhibitor		WO 2015008073			
ADR000382	ML-396; VU-0422288; VU-0422288-1	Preclinical	Depression; Attention deficit hyperactivity disorder (ADHD); Schizophrenia; Autism	C17H11Cl2N3O2	Metabotropic glutamate receptor 4;Metabotropic glutamate receptor 7;Metabotropic glutamate receptor 8	ASD01900000_1;ASD01920000_2;ASD05180000_1	Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1	ASD01920025	Activator;Activator;Activator					
ADR000383		Preclinical	Psychosis	C19H16FN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)N1CCc2nc(COc3ccccc3)cn2C1=O	ASD01914334	Activator		WO 2012125732			
ADR000384	PF-06462894	Preclinical	Parkinson's disease	C19H24N2O3	Metabotropic glutamate receptor 5	ASD01910000_1	CC(C)(C)C[C@@H]1COCC2=NC(OCc3ccccn3)=CC(=O)N12 |c:20,t:9|	ASD01918533	Inhibitor					
ADR000385	ODM-106	Phase I	Tremor, essential		Gamma-aminobutyric acid type B receptor	ASD01150000_1			Activator					
ADR000386		Preclinical	Depression	C18H13ClF2N4O	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(nc1)-c1cc2CN(CCn2n1)C(=O)c1cc(F)cc(Cl)c1	ASD01917729	Inhibitor		JP 2015059118			
ADR000387	GNE-0723	Preclinical	Neurological Disorders; Psychiatric Disorders	C16H8ClF6N5OS	Glutamate receptor ionotropic, NMDA 2A	ASD02030000_4	FC(F)(F)C1=C([C@@H]2C[C@H]2C#N)N2C(S1)=NC(Cn1nc(cc1Cl)C(F)(F)F)=CC2=O |c:4,15,29|	ASD02030373	Activator		WO 2015052226			
ADR000388	ASP-4345	Phase II	Schizophrenia; Cognitive disorders		D(1A) dopamine receptor	ASD13110000_1			Activator					
ADR000389		Preclinical	Autism spectrum disorders; Obsessive-compulsive disorder; Other neurological disorders	C17H10F2N6O2	Sodium-dependent dopamine transporter;Metabotropic glutamate receptor 5	ASD06560000_1;ASD01910000_1	Fc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ncnc23)nc1	ASD01917922	Inhibitor;Inhibitor		WO 2015077246			
ADR000390		Preclinical	Autism spectrum disorders; Obsessive-compulsive disorder; Other neurological disorders	C17H10F2N6O2	Sodium-dependent dopamine transporter;Metabotropic glutamate receptor 5	ASD06560000_1;ASD01910000_1	Fc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3cnnc23)nc1	ASD01917670	Inhibitor;Inhibitor		WO 2015077246			
ADR000391		Preclinical	Anxiety disorder	C19H21Cl2N5OS	Metabotropic glutamate receptor 5	ASD01910000_1	Cl[H].CCC[C@@H](NC(=O)c1nccs1)c1cnc(Nc2ccc(C)nc2)c(Cl)c1	ASD01918557	Inhibitor		WO 2015098991			
ADR000392		Preclinical	Anxiety disorder	C19H18ClN5OS	Metabotropic glutamate receptor 5	ASD01910000_1	Cl[H].Cc1ccc(Nc2ncc(cc2Cl)[C@@H](CC=C)NC(=O)c2nccs2)cn1	ASD01918559	Inhibitor		WO 2015098991			
ADR000393	S-44858	Preclinical	Cognitive disorders		Glutamate receptor 1	ASD03930000_1			Activator					
ADR000394	VU-0413846	Preclinical	Psychosis	C20H16F2N2O3	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)C(=O)N1CCc2nc(COc3cccc(F)c3)oc2C1	ASD01917760	Activator		WO 2012031024			
ADR000395	VU-0457481	Preclinical	Psychosis	C20H19N5O3	Metabotropic glutamate receptor 5	ASD01910000_1	O=C(N1CCC2N=C(COc3ccccc3)OC2C1)c1n[nH]c2ncccc12 |t:6|	ASD01918564	Activator		WO 2012031024			
ADR000396	BMS-986163	Preclinical	Depression	C23H28FN2O5P	Glutamate receptor ionotropic, NMDA 2B	ASD11000000_1	Cc1ccc(CN2CC[C@@H](N3CC[C@H]([C@H](F)C3)c3ccc(OP(O)(O)=O)cc3)C2=O)cc1	ASD11000257	Inhibitor		US 2015191496; US 2016030456; US 2017065573; US 2017216325; US 2017340653; US 2018104265; US 2018250316			
ADR000397		Preclinical	Parkinson's disease; Metabolic syndrome	C13H10ClN3	Metabotropic glutamate receptor 4;Fatty acid desaturase 1	ASD01900000_1;ASD13180000_1	Clc1cccc(Nc2n[nH]c3ccccc23)c1	ASD01901120	Activator;Inhibitor		WO 2008089307; WO 2008089310			
ADR000398	BMS-986165	Phase III	Psoriasis, plaque; Arthritis, psoriatic; Crohn's disease; Systemic lupus erythematosus	C19H17D3N8O2	Metabotropic glutamate receptor 4	ASD01900000_1	[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC	ASD01901528	Inhibitor		WO 2014074661; WO 2018183649; WO 2018183656			
ADR000399		Preclinical	Parkinson's disease	C23H16F3N5O	Metabotropic glutamate receptor 2;Metabotropic glutamate receptor 3	ASD01880000_1;ASD05170000_1	Nc1ccc(cn1)-c1ccc2C(=O)N(CC(F)(F)F)c3cc(nn3-c2c1)-c1ccccc1	ASD01884384	Inhibitor;Inhibitor		WO 2013174822			
ADR000401	VU-0650786	Preclinical	Anxiety disorder; Depression	C18H15ClFN5O2	Metabotropic glutamate receptor 3	ASD05170000_1	C[C@@H]1CN(C(=O)c2cc(COc3ccc(Cl)cn3)nn12)c1cccnc1F	ASD05170037	Inhibitor		WO 2012083224			
ADR000402		Preclinical	Anxiety disorder; Depression	C19H15ClN6O2	Metabotropic glutamate receptor 3	ASD05170000_1	C[C@@H]1CN(C(=O)c2cc(COc3ccc(Cl)cn3)nn12)c1cncc(c1)C#N	ASD05170123	Inhibitor		WO 2012083224			
ADR000404	VU-0486321	Preclinical	Schizophrenia	C20H12ClFN2O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(F)c3C2=O)c(Cl)c1	ASD01870290	Activator					
ADR000405		Preclinical	Autism spectrum disorders; Pain; Anxiety disorder; Fragile X syndrome; Parkinson's disease; Gastroesophageal reflux disease (GERD); Cancer; Substance abuse and dependence	C19H13N5O2S	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1csc(NC(=O)c2cc(cc3cccnc23)C(=O)c2cncnc2)n1	ASD01918565	Inhibitor		US 2015266866			
ADR000407	VU-0462807	Preclinical	Rett syndrome; Psychosis	C15H17N3O2	Metabotropic glutamate receptor 5	ASD01910000_1	CC(=O)N1CCCn2nc(COc3ccccc3)cc12	ASD01918026	Activator					
ADR000408		Preclinical	Psychosis	C15H16FN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	CC(=O)N1CCCn2nc(COc3cccc(F)c3)cc12	ASD01918112	Activator					
ADR000409		Preclinical	Psychosis	C16H20N4O	Metabotropic glutamate receptor 5	ASD01910000_1	CN(Cc1cc2N(CCCn2n1)C(C)=O)c1ccccc1	ASD01918118	Activator					
ADR000410		Preclinical	Psychosis	C17H20N4O2	Metabotropic glutamate receptor 5	ASD01910000_1	CC(=O)N1CCCn2nc(CN3CCOc4ccccc34)cc12	ASD01918120	Activator					
ADR000411		Preclinical	Cognitive disorders	C18H21FN6	Metabotropic glutamate receptor 5	ASD01910000_1	CC(C)(C)n1nnc2CC(CCc12)n1cnc(n1)-c1ccc(F)cc1	ASD01918577	Activator					
ADR000412		Preclinical	Cognitive disorders	C18H20FN5O	Metabotropic glutamate receptor 5	ASD01910000_1	CC(C)(C)n1nnc2CC(CCc12)c1nc(no1)-c1ccc(F)cc1	ASD01918064	Activator					
ADR000413		Preclinical	Cognitive disorders	C18H17FN6O	Metabotropic glutamate receptor 5	ASD01910000_1	CC(C)(C#N)n1nnc2CC(CCc12)c1nc(no1)-c1ccc(F)cc1	ASD01918067	Activator					
ADR000414		Preclinical	Pain	C25H18Cl3NO	Adenosine receptor A1	ASD00170000_1	Nc1sc(c(Cc2ccc(Cl)cc2)c1C(=O)c1ccc(Cl)cc1)-c1ccc(Cl)cc1	ASD00170525	Activator					
ADR000415	[11C]MK-6884	Phase I	Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M4	ASD01840000_1			Regulator					
ADR000416	BMS-986169	Preclinical	Depression	C23H27FN2O2	Glutamate receptor ionotropic, NMDA 2B	ASD11000000_1	Cc1ccc(CN2CC[C@@H](N3CC[C@H]([C@H](F)C3)c3ccc(O)cc3)C2=O)cc1	ASD02030713	Inhibitor		US 2015191452; US 2016081995; US 2017258777; US 2018000807; US 2018110766; US 2018250283			
ADR000417	BMT-108908	Preclinical	Depression	C22H25FN2O2	Glutamate receptor ionotropic, NMDA 2B	ASD11000000_1	Oc1ccc(cc1)C1CCN(CC1)[C@@H]1CCN(Cc2ccc(F)cc2)C1=O	ASD11000155	Inhibitor		US 2015191452			
ADR000418		Preclinical	Depression; Psychosis	C21H14FN3O3	Metabotropic glutamate receptor 2	ASD01880000_1	NC(=O)C1=CN(c2ccc(F)cc2)c2ccc(Oc3cccnc3)cc2C1=O |t:3|	ASD01884392	Inhibitor					
ADR000419		Preclinical	Depression; Psychosis	C22H17FN4O2	Metabotropic glutamate receptor 2	ASD01880000_1	NC(=O)C1=CN(c2ccc(F)cc2)c2ccc(NCc3cccnc3)cc2C1=O |t:3|	ASD01884472	Inhibitor					
ADR000420		Preclinical	Depression; Psychosis	C22H20F3N3O2	Metabotropic glutamate receptor 2	ASD01880000_1	NC(=O)C1=CN(c2ccc(F)cc2)c2ccc(CN3CCC(F)(F)CC3)cc2C1=O |t:3|	ASD01884478	Inhibitor					
ADR000421	VU-6001192	Preclinical	Depression; Psychosis	C23H24FN3O3	Metabotropic glutamate receptor 2	ASD01880000_1	C[C@H]1CN(Cc2ccc3N(C=C(C(N)=O)C(=O)c3c2)c2ccc(F)cc2)C[C@@H](C)O1 |r,t:10|	ASD01882936	Inhibitor					
ADR000422		Preclinical	Depression; Psychosis	C23H19FN4O2	Metabotropic glutamate receptor 2	ASD01880000_1	Cc1ncc(CCc2ccc3N(C=C(C(N)=O)C(=O)c3c2)c2ccc(F)cc2)cn1 |t:12|	ASD01883116	Inhibitor					
ADR000423	PF-06764427	Preclinical	Schizophrenia; Cognitive disorders	C24H25N5O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1ccc(n1)-c1ccc(Cn2cc(C(=O)N[C@H]3CCOC[C@@H]3O)c3ncccc23)cc1	ASD01813296	Regulator					
ADR000424	DT-1687; PXT-002331; PXT-2331; FR50CP1D6W (Unique Ingredient Identifier (UNII) code), Foliglurax(Rec INN)	Phase II	Parkinson's disease	C24H25N3O2S	Metabotropic glutamate receptor 4	ASD01900000_1	O\N=C1/C=C(Oc2ccc(CCCN3CCOCC3)cc12)c1cc2sccc2cn1 |c:3|	ASD01901537	Activator		WO 2016030444; WO 2017032874			
ADR000425		Preclinical	Psychosis	C19H16FN3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)N1CCn2nc(OCc3ccccc3)cc2C1=O	ASD01917209	Activator		WO 2013192343			
ADR000426		Preclinical	Autism spectrum disorders; Pain; Anxiety disorder; Depression; Fragile X syndrome; Parkinson's disease; Gastroesophageal reflux disease (GERD); Substance abuse and dependence	C15H17N3O3S	Metabotropic glutamate receptor 5	ASD01910000_1	Cc1csc(NC(=O)c2cc(O[C@@H]3CCOC3)cc(C)n2)n1	ASD01918584	Inhibitor		WO 2015200682			
ADR000427		Preclinical	Cognitive disorders; Psychosis	C23H23N5O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	O[C@H]1COCC[C@@H]1NC(=O)c1cn(Cc2ccc(cc2)-n2cccn2)c2cccnc12	ASD01811864	Regulator					
ADR000428		Preclinical	Schizophrenia	C20H12Cl2N2O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(Cl)cc3C2=O)c(Cl)c1	ASD01870639	Activator					
ADR000429		Preclinical	Schizophrenia	C19H12ClN3O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccncc3C2=O)c(Cl)c1	ASD01870642	Activator					
ADR000430	PF-06767832	Preclinical	Schizophrenia; Dementia, Alzheimer's type	C22H23N3O3S	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1cnc(cc1Cc1ccc(cc1)-c1cscn1)C(=O)N[C@H]1CCOC[C@@H]1O	ASD01811853	Activator		WO 2016009297			
ADR000431	5PAM-523	Preclinical	Psychosis	C20H18F2N4O2	Metabotropic glutamate receptor 5	ASD01910000_1	C[C@@H]1CC[C@@H](CN1C(=O)c1ccc(F)cc1)c1noc(n1)-c1ccc(F)cn1	ASD01915346	Activator		WO 2010124055			
ADR000432		Preclinical	Psychosis	C21H15FN2O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(cc1F)N1C(=O)c2cccc(C)c2C1=O	ASD01870510	Activator					
ADR000433	VU-6004909	Preclinical	Psychosis	C21H15FN2O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(cc1F)N1C(=O)c2ccc(C)cc2C1=O	ASD01870308	Activator					
ADR000434		Preclinical	Psychosis	C20H12ClFN2O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(cc1F)N1C(=O)c2cccc(Cl)c2C1=O	ASD01870512	Activator					
ADR000435		Preclinical	Psychosis	C20H12F2N2O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(cc1F)N1C(=O)c2cccc(F)c2C1=O	ASD01870513	Activator					
ADR000436		Preclinical	Psychosis	C20H12F2N2O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(cc1F)N1C(=O)c2ccc(F)cc2C1=O	ASD01870514	Activator					
ADR000437		Preclinical	Psychosis	C20H13FN2O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(cc1F)N1C(=O)c2ccccc2C1=O	ASD01870468	Activator					
ADR000438		Preclinical	Psychosis	C20H13ClN2O4	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(cc1Cl)N1C(=O)c2ccccc2C1=O	ASD01870624	Activator					
ADR000439		Preclinical	Psychosis	C22H29N3O2	Metabotropic glutamate receptor 2	ASD01880000_1	CN1C(=O)N(CC(C)(C)C)c2ccc(nc12)-c1cc(ccc1C)C(C)(C)O	ASD01882283	Activator		WO 2011156245			
ADR000440	RGH-618	Phase I	Anxiety disorder	C22H12ClFN2O2S	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc2c(-c3ccc(Cl)cc3)c(cnc2c1)S(=O)(=O)c1cccc(c1)C#N	ASD01918590	Inhibitor		WO 2008155588			
ADR000441	SAGE-718	Phase I	Encephalitis; Smith-Lemli-Opitz syndrome; Huntington's disease		Glutamate receptor ionotropic, NMDA 2B	ASD11000000_1			Regulator					
ADR000442	SAGE-324	Phase I	Neurological Disorders; Tremor, essential; Parkinson's disease		Gamma-aminobutyric acid-A receptor	ASD01140000_1			Activator					
ADR000443	VU-0467558	Preclinical	Anxiety disorder; Parkinson's disease; Gastroesophageal reflux disease (GERD); Substance abuse and dependence	C17H21N5	Metabotropic glutamate receptor 1;Metabotropic glutamate receptor 5	ASD01870000_1;ASD01910000_1	CC1(C)CCC(CC1)Nc1ncnc2c1nn1ccccc21	ASD01870549	Inhibitor;Inhibitor					
ADR000444	VU-0487351	Preclinical	Schizophrenia	C20H14Cl2N2O3	Metabotropic glutamate receptor 1	ASD01870000_1	Cc1ccoc1C(=O)Nc1ccc(N2Cc3c(cccc3Cl)C2=O)c(Cl)c1	ASD01870310	Activator					
ADR000445	VU-0477573	Preclinical	Anxiety disorder	C18H17FN2O	Metabotropic glutamate receptor 5	ASD01910000_1	CCN(CC)C(=O)c1ccc(cn1)C#Cc1cccc(F)c1	ASD01915458	Inhibitor		WO 2013049255			
ADR000446	ABI-H-0731; ABI-H0731	Phase II	Hepatitis B, chronic		Capsid protein	ASD15280000_1			Regulator					
ADR000447	TAK-071	Phase I	Lewy body dementia; Neurological Disorders; Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M1	ASD01810000_1			Activator					
ADR000448	VU-0477886	Preclinical	Parkinson's disease	C20H13ClN4O3	Metabotropic glutamate receptor 4	ASD01900000_1	Nc1cccnc1C(=O)Nc1ccc(N2C(=O)c3ccccc3C2=O)c(Cl)c1	ASD01900614	Activator					
ADR000449	VU-0483872	Preclinical	Parkinson's disease	C18H16ClN5O2	Metabotropic glutamate receptor 4	ASD01900000_1	CCc1cnc(Oc2ccc(NC(=O)c3ncccc3N)cc2Cl)nc1	ASD01900821	Activator					
ADR000450	RPC-8844	Preclinical	Non-alcoholic steatohepatitis; Diabetes type 2; Obesity		Glucagon-like peptide 1 receptor	ASD01180000_1			Activator					
ADR000451	SUVN-I4035	Preclinical	Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M1	ASD01810000_1			Activator					
ADR000452	CTW-0415	Preclinical	Substance abuse and dependence	C15H22N2O3	5-hydroxytryptamine receptor 2C	ASD00110000_1	OC[C@@H](O)CNC(=O)C1CC(CCN1)c1ccccc1	ASD00110051	Regulator		WO 2013086266			
ADR000453	ONO-8590580	Preclinical	Cognitive disorders	C21H21FN6	Gamma-aminobutyric acid receptor subunit alpha-5	ASD01140000_15	Cc1c(F)c(Nc2ccc(cn2)-c2cn(C)cn2)cc2n(CC3CC3)cnc12	ASD01140679	Inhibitor		WO 2015115673			
ADR000454	VU-0486384	Preclinical	Dementia, Alzheimer's type; Psychosis	C22H15F2N5O	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1cc2cc(ccc2n1)-c1cc(F)c(CN2C(=O)C=Nc3ncccc23)c(F)c1 |c:21|	ASD01811471	Activator		WO 2014179226			
ADR000455	VU-0483225	Preclinical	Dementia, Alzheimer's type; Psychosis	C23H14F2N4O	Muscarinic acetylcholine receptor M1	ASD01810000_1	Fc1cc(cc(F)c1CN1C=Nc2cnccc2C1=O)-c1ccc2cnccc2c1 |c:11|	ASD01811474	Activator					
ADR000456	VU-0486691	Preclinical	Dementia, Alzheimer's type; Psychosis	C21H17F2N5O	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1cc2c(cccc2n1)-c1cc(F)c(CN2C=CC3=NCCN3C2=O)c(F)c1 |c:19,t:21|	ASD01813459	Activator					
ADR000457		Preclinical	Epilepsy; Neurodegeneration	C24H28N2O2	Glutamate receptor ionotropic, NMDA 2B	ASD11000000_1	CCc1ccc(CC2CCN(CC(=O)c3c[nH]c4ccc(O)cc34)CC2)cc1	ASD11000290	Inhibitor					
ADR000458		Preclinical	Epilepsy; Neurodegeneration	C23H26N2O2	Glutamate receptor ionotropic, NMDA 2B	ASD11000000_1	Cc1ccc(CC2CCN(CC(=O)c3c[nH]c4ccc(O)cc34)CC2)cc1	ASD11000285	Inhibitor					
ADR000459	BMS-952048	Preclinical	Schizophrenia; Cognitive disorders	C21H13F2N3O2	Metabotropic glutamate receptor 5	ASD01910000_1	Fc1ccc(cc1)[C@H]1OC(=O)N[C@@H]1c1cncc(c1)C#Cc1ncccc1F	ASD01917541	Activator		WO 2012064603			
ADR000460		Preclinical	Cognitive disorders; Psychosis; Other neurological disorders	C17H15N3O2S	Muscarinic acetylcholine receptor M4	ASD01840000_1	Nc1c(sc2nc(O)c3CCCCc3c12)C(=O)c1ccncc1	ASD01840044	Activator					
ADR000461		Preclinical	Cognitive disorders; Psychosis; Other neurological disorders	C22H24N4O3S	Muscarinic acetylcholine receptor M4	ASD01840000_1	Nc1c(sc2nc(OCCN3CCOCC3)c3CCCc3c12)C(=O)c1ccncc1	ASD01840046	Activator					
ADR000462	ABD-1075	Preclinical	Diabetes type 2; Obesity; Substance abuse and dependence	C20H14ClF2N3O2S	Cannabinoid receptor 1	ASD03330000_1	Fc1ccc(c(F)c1)-c1ccc(CNS(=O)(=O)c2cc3cc(Cl)ccc3[nH]2)nc1	ASD03331790	Regulator		WO 2012117216			
ADR000463	ABD-1085	Preclinical	Diabetes type 2; Obesity; Substance abuse and dependence	C20H14ClF2N3O2S	Cannabinoid receptor 1	ASD03330000_1	Fc1ccc(c(F)n1)-c1ccc(CNS(=O)(=O)c2cc3cc(Cl)ccc3[nH]2)cc1	ASD03331791	Regulator		WO 2012117216			
ADR000464	KRM-II-81	Preclinical	Epilepsy; Pain; Anxiety disorder	C21H13N5O	Gamma-aminobutyric acid receptor subunit alpha-3	ASD01140000_13	C#Cc1ccc-2c(c1)C(=NCc1c(ncn-21)-c1cnco1)c1ccccn1 |c:9|	ASD01140680	Activator		WO 2016154031			
ADR000465	JNJ-46356479; JNJ-479	Preclinical	Epilepsy; Anxiety disorder; Schizophrenia; Sleep disorder	C22H22F5N5	Metabotropic glutamate receptor 2	ASD01880000_1	Fc1ccc(N2CCN(Cc3ccn4c(CC5CC5)nnc4c3C(F)(F)F)CC2)c(F)c1	ASD01882443	Activator		WO 2010130424; WO 2015110435			
ADR000466	GNE-5729	Preclinical	Neurological Disorders; Psychiatric Disorders	C17H10Cl2F3N5O	Glutamate receptor ionotropic, NMDA 2A	ASD02030000_4	FC(F)(F)c1cc(Cl)n(CC2=CC(=O)N3C(C=CC(Cl)=C3[C@@H]3C[C@H]3C#N)=N2)n1 |c:16,19,27,t:10|	ASD02030774	Activator		WO 2016166078			
ADR000467	UCM-1212	Preclinical	Parkinson's disease	C14H11FO2	D(1A) dopamine receptor	ASD13110000_1	FCOc1ccccc1-c1ccc(C=O)cc1	ASD13110012	Activator					
ADR000468		Preclinical	Parkinson's disease	C12H8ClN3O	Metabotropic glutamate receptor 4	ASD01900000_1	Clc1cccc(Nc2noc3cccnc23)c1	ASD01900498	Activator		WO 2011100614			
ADR000469	ASP-8302	Phase II	Detrusor underactivity (Underactive bladder)		Muscarinic acetylcholine receptor M3	ASD01830000_1			Activator					
ADR000470	VA-012	Preclinical	Obesity	C20H17N3	5-hydroxytryptamine receptor 2C	ASD00110000_1	C(Nc1cccnc1)c1cn(Cc2ccccc2)c2ccccc12	ASD00110052	Regulator					
ADR000471	E-039132; ETx-9132	Preclinical	Cancer		Indoleamine 2,3-dioxygenase 1	ASD08570000_1			Inhibitor					
ADR000472	E-040280; ETx-0280	Preclinical	Cancer		Indoleamine 2,3-dioxygenase 1	ASD08570000_1			Inhibitor					
ADR000473	BMT-145027	Preclinical	Schizophrenia	C23H14ClF3N4	Metabotropic glutamate receptor 5	ASD01910000_1	FC(F)(F)c1cc(ccc1Cl)-c1n[nH]c2nc(-c3ccccc3)c(C#N)c(C3CC3)c12	ASD01915423	Activator					
ADR000474	DK-I-56-1	Preclinical	Neuralgia, trigeminal; Migraine; Depression; Attention deficit hyperactivity disorder (ADHD); Schizophrenia; Tinnitus; Huntington's disease; Tic disorder	C18H12D3N3O3	Gamma-aminobutyric acid receptor subunit alpha-6;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_16;ASD01140000_10;ASD01140000_1	[2H]C([2H])([2H])Oc1ccc(cc1)N1N=C2C(=CNc3cc(OC)ccc23)C1=O |c:13,15|	ASD01140681	Activator;Activator;Activator		WO 2016196961			
ADR000475	DK-I-86-1	Preclinical	Neuralgia, trigeminal; Migraine; Depression; Attention deficit hyperactivity disorder (ADHD); Schizophrenia; Tinnitus; Huntington's disease; Tic disorder	C17H11D3N4O3	Gamma-aminobutyric acid receptor subunit alpha-6;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_16;ASD01140000_10;ASD01140000_1	[2H]C([2H])([2H])Oc1ccc2C3=NN(C(=O)C3=CNc2c1)c1ccc(OC)nc1 |c:15,t:9|	ASD01140684	Activator;Activator;Activator		WO 2016196961			
ADR000476		Preclinical	Schizophrenia; Cognitive disorders	C20H14Cl2F2N2O2	Metabotropic glutamate receptor 5	ASD01910000_1	FC1(F)CC(C1)C#Cc1cncc(c1)[C@H]1NC(=O)O[C@@H]1c1cccc(Cl)c1Cl	ASD01918618	Activator		WO 2015054103			
ADR000477	DETQ	Preclinical	Neurodegeneration	C22H25Cl2NO3	D(1A) dopamine receptor	ASD13110000_1	C[C@@H]1N([C@@H](CO)Cc2c1cccc2C(C)(C)O)C(=O)Cc1c(Cl)cccc1Cl	ASD13110005	Activator		WO 2014193781			
ADR000478	VU-0468182	Preclinical	Cognitive disorders; Psychosis; Huntington's disease	C17H16F2N4O3S2	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)NCc3ccc(cc3)S(=O)(=O)C(F)F)c(N)c2c1C	ASD01840017	Activator		WO 2013126856			
ADR000479	VU-0469785	Preclinical	Cognitive disorders; Psychosis; Huntington's disease	C16H15F5N4OS2	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)NCc3ccc(cc3)S(F)(F)(F)(F)F)c(N)c2c1C	ASD01840020	Activator		WO 2013126856			
ADR000480		Preclinical	Migraine	C23H20N4O4	Cysteinyl leukotriene receptor 1;Metabotropic glutamate receptor 2	ASD13200000_1;ASD01880000_1	CC(=O)c1ccc(OCc2ccc(Oc3cccc(c3)-c3nn[nH]n3)cc2)c(C)c1O	ASD01885005	Inhibitor;Activator		WO 2006057860			
ADR000481		Preclinical	Migraine	C22H16F3N5O4	Cysteinyl leukotriene receptor 1;Metabotropic glutamate receptor 2	ASD13200000_1;ASD01880000_1	CC(=O)c1ccc(OCc2cccc(Oc3cc(ccn3)-c3nn[nH]n3)c2)c(c1O)C(F)(F)F	ASD01885006	Inhibitor;Activator		WO 2006057860			
ADR000482	VU-6004256	Preclinical	Psychosis	C25H25F2N5O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1cc(cn1)-c1ccc(Cn2cc(C(=O)N[C@H]3CCCC[C@@H]3O)c3c(F)cc(F)cc23)cn1	ASD01810726	Activator		WO 2013106795			
ADR000483		Preclinical	Anesthesia	C12H9F3N2O2	Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit beta2;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_3;ASD01140000_2;ASD01140000_1	Oc1cc(ccc1COCC#C)C1(N=N1)C(F)(F)F |c:14|	ASD01140693	Activator;Activator;Activator					
ADR000484	BMT-133218	Preclinical	Schizophrenia	C21H19ClF3N3O	Metabotropic glutamate receptor 2	ASD01880000_1	FC(F)(F)c1c(OC[C@H]2C[C@@H]2c2ccc(Cl)cc2)ccn2c(CC3CC3)nnc12	ASD01883871	Activator		WO 2015042243			
ADR000485		Preclinical	Diabetes type 2	C29H29FO4	Free fatty acid receptor 1	ASD09380000_1	COc1ccc(F)c(c1)-c1ccc(cc1)[C@@H]1CCc2ccc(cc2O1)[C@@H]([C@H](C)C(O)=O)C1CC1	ASD09380014	Activator		CN 105232544; CN 105476990; CN 105520943; WO 2014130608; WO 2016022448			
ADR000486		Preclinical	Diabetes type 2	C29H29FO4	Free fatty acid receptor 1	ASD09380000_1	COc1ccc(F)c(c1)-c1ccc(cc1)[C@H]1CCc2ccc(cc2O1)[C@@H]([C@H](C)C(O)=O)C1CC1	ASD09380015	Activator		WO 2014130608; WO 2016022448			
ADR000487		Preclinical	Diabetes type 2		Free fatty acid receptor 1	ASD09380000_1	COc1ccc(F)c(c1)-c1ccc(nc1)C1CCc2ccc(cc2O1)[C@@H]([C@H](C)C(O)=O)C1CC1		Activator		WO 2014130608; WO 2016022448			
ADR000488		Preclinical	Diabetes type 2		Free fatty acid receptor 1	ASD09380000_1	CO[C@@H](c1cc(ccc1-c1cc(OC)ccc1F)C1CCc2ccc(cc2O1)[C@@H](CC(O)=O)C1CC1)C(C)(C)C		Activator		WO 2014130608			
ADR000489	AZ-13713945 (free base); VU-0467485 (free base)	Preclinical	Schizophrenia		Muscarinic acetylcholine receptor M4	ASD01840000_1	Cl[H].COc1ccc(CNC(=O)c2sc3nnc(C)c(C)c3c2N)cc1F		Activator		WO 2013126856			
ADR000490	VU-6008667	Preclinical	Substance abuse and dependence	C24H17ClF2N2O2	Muscarinic acetylcholine receptor M5	ASD01850000_1	Cc1cc(ccc1Cl)[C@]12N(CCN1C(=O)c1ccccc21)C(=O)c1ccc(F)c(F)c1	ASD01850139	Inhibitor					
ADR000491	JF-NP-26	Preclinical	Pain	C30H28FN3O4	Metabotropic glutamate receptor 5	ASD01910000_1	CCN(CC)c1ccc2C(COC(=O)Nc3c(C)cc(C)nc3C#Cc3cccc(F)c3)=CC(=O)Oc2c1 |c:33|	ASD01918623	Inhibitor					
ADR000492		Preclinical	Pain	C16H18N4O2	Metabotropic glutamate receptor 5	ASD01910000_1	COc1cc(ccc1NC(=O)C(C)C)\N=N\c1ccccn1	ASD01918185	Inhibitor		WO 2015044358			
ADR000493		Preclinical	Pain	C19H22N4O2	Metabotropic glutamate receptor 5	ASD01910000_1	COc1cc(ccc1NC(=O)C1CCCCC1)\N=N\c1ccccn1	ASD01918186	Inhibitor		WO 2015044358			
ADR000494		Preclinical	Pain	C19H16FN5O2	Metabotropic glutamate receptor 5	ASD01910000_1	COc1cc(ccc1NC(=O)Nc1ccccc1F)\N=N\c1ccccn1	ASD01918199	Inhibitor		WO 2015044358			
ADR000495	A-1553307	Preclinical	Epilepsy	C23H21ClN4O4	Gamma-aminobutyric acid type B receptor	ASD01150000_1	COc1ccc(NC(C)=O)cc1C1=NN([C@@H](C)c2ccc(Cl)cc2)C(=O)c2c(C)noc12 |t:13|	ASD01151068	Activator		US 2017073353			
ADR000496		Preclinical	Cognitive disorders	C20H20F4N4O	Metabotropic glutamate receptor 2;Metabotropic glutamate receptor 3	ASD01880000_1;ASD05170000_1	C[C@H](O)Cn1nc(cc1N(C)c1ccc(c(F)c1)C(F)(F)F)-c1ccnc(C)c1	ASD01883712	Regulator;Inhibitor					
ADR000497		Preclinical	Cognitive disorders	C19H17ClF4N4O	Metabotropic glutamate receptor 2;Metabotropic glutamate receptor 3	ASD01880000_1;ASD05170000_1	C[C@H](O)Cn1nc(c(Cl)c1Nc1ccc(c(F)c1)C(F)(F)F)-c1ccnc(C)c1	ASD01885029	Regulator;Inhibitor					
ADR000498		Preclinical	Cognitive disorders	C20H19ClF4N4O	Metabotropic glutamate receptor 2;Metabotropic glutamate receptor 3	ASD01880000_1;ASD05170000_1	C[C@H](O)Cn1nc(c(Cl)c1N(C)c1ccc(c(F)c1)C(F)(F)F)-c1ccnc(C)c1	ASD01885030	Regulator;Inhibitor					
ADR000499		Preclinical	Cognitive disorders	C22H25F3N4O2	Metabotropic glutamate receptor 2;Metabotropic glutamate receptor 3	ASD01880000_1;ASD05170000_1	CCOc1cc(ccc1C(F)(F)F)N(C)c1cc(nn1C[C@H](C)O)-c1ccnc(C)c1	ASD01885032	Regulator;Inhibitor					
ADR000500	MYK-491; SAR-440181	Phase I	Cardiomyopathy, dilated (congestive)		Cardiac myosin heavy chain	ASD08190000_1			Inhibitor					
ADR000501	(-)-(S)-B-973B; B-973	Preclinical	Pain; Psychosis	C24H26F2N6O	Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	C[C@H](NC(=O)CCc1ccc(F)c(F)c1)c1cncc(n1)N1CCN(CC1)c1ccccn1	ASD03091894	Activator					
ADR000502		Preclinical	Parkinson's disease	C21H19N5OS	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)NCc3ccc(cc3)-c3ccncc3)c(N)c2c1C	ASD01840115	Activator		WO 2013126856			
ADR000503		Preclinical	Parkinson's disease	C21H18FN5OS	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)NCc3ccc(cc3)-c3ccnc(F)c3)c(N)c2c1C	ASD01840124	Activator		WO 2013126856			
ADR000504		Preclinical	Parkinson's disease	C21H18FN5OS	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)NCc3ccc(cc3)-c3ccc(F)nc3)c(N)c2c1C	ASD01840126	Activator		WO 2013126856			
ADR000505	VU-0476406	Preclinical	Parkinson's disease	C21H18FN5OS	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)NCc3ccc(cc3)-c3cccnc3F)c(N)c2c1C	ASD01840129	Activator		WO 2013126856			
ADR000506		Preclinical	Spasm, smooth muscle	C21H14FN3O2	Gamma-aminobutyric acid receptor subunit alpha-5	ASD01140000_15	C[C@H]1N=C(c2ccccc2F)c2cc(ccc2-n2cnc(C(O)=O)c12)C#C |t:2|	ASD01140577	Activator		WO 2006004945			
ADR000507	SSD-114	Preclinical	Anxiety disorder; Depression; Substance abuse and dependence	C18H20F3N3O	Gamma-aminobutyric acid type B receptor	ASD01150000_1	COc1cc(nc(NC2CCCCC2)n1)-c1ccc(cc1)C(F)(F)F	ASD01150344	Activator					
ADR000508	VU-6000918	Preclinical	Schizophrenia; Psychosis	C18H17F2N5OS	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)NC3CN(C3)c3cccc(F)c3F)c(N)c2c1C	ASD01840191	Activator		WO 2013126856			
ADR000509	Niclosamide ethanolamine	Preclinical	Diabetes type 2; Cancer	C15H15Cl2N3O5	Cytochrome P450 1A2;Neuropeptide Y receptor type 4	ASD13210000_1;ASD13410000_1	NCCO.Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	ASD13210004	Inhibitor;Activator		CN 106420684; CN 106727472; CN 108434130; WO 2009032749; WO 2012068274; WO 2018053954			
ADR000510		Preclinical	Psychosis	C18H18FN3O	Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit beta2;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_3;ASD01140000_2;ASD01140000_1	CCC(=O)NCc1c(nc2ccc(C)cn12)-c1ccc(F)cc1	ASD01140626	Activator;Activator;Activator					
ADR000511	SUVN-I-6107	Preclinical	Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M1	ASD01810000_1			Activator					
ADR000512	[11C]QCA	Preclinical	Diagnostics		Metabotropic glutamate receptor 2	ASD01880000_1	[11CH3]Oc1ccc(c(F)c1)-c1cc(nc2cc(CN3C(=O)CCC3=O)ccc12)C(N)=O		Inhibitor					
ADR000513	VU-319	Phase I	Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M1	ASD01810000_1			Activator					
ADR000514	MP-III-024	Preclinical	Hyperalgesia	C20H14N4O2	Gamma-aminobutyric acid receptor subunit alpha-3	ASD01140000_13	COC(=O)c1ncn-2c1CN=C(c1ccccn1)c1cc(ccc-21)C#C |t:11|	ASD01140581	Activator					
ADR000515	CAD-1883	Phase II	Tremor, essential; Spinocerebellar ataxia		Sodium-dependent dopamine transporter	ASD06560000_1			Activator					
ADR000516	DK-II-60-1	Preclinical	Neuralgia, trigeminal; Migraine; Depression; Attention deficit hyperactivity disorder (ADHD); Schizophrenia; Tinnitus; Huntington's disease; Tic disorder	C17H11D3N4O3	Gamma-aminobutyric acid receptor subunit alpha-6;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_16;ASD01140000_10;ASD01140000_1	[2H]C([2H])([2H])Oc1ccc(cn1)N1N=C2C(=CNc3cc(OC)ccc23)C1=O |c:13,15|	ASD01140709	Activator;Activator;Activator		WO 2016196961			
ADR000517		Preclinical	Epilepsy; Anxiety disorder; Mood disorder; Schizophrenia; Eating disorder; Cognitive disorders; Substance abuse and dependence	C24H20F4N4O	Metabotropic glutamate receptor 2	ASD01880000_1	Cc1ccc(Oc2ccc(cc2F)-c2ccn3c(CC4CC4)nnc3c2C(F)(F)F)c(C)n1	ASD01885541	Activator		WO 2010130423			
ADR000518	PF-06827443	Preclinical	Schizophrenia; Cognitive disorders		Muscarinic acetylcholine receptor M1	ASD01810000_1	Cc1cc2CN([C@H]3CCOC[C@@H]3O)C(=O)c2cc1Cc1ccc(cc1)-c1cocn1		Activator					
ADR000519	VU-6009289	Preclinical	Schizophrenia		Muscarinic acetylcholine receptor M4	ASD01840000_1	COc1ccc2CN(CCc2c1)C(=O)C1CCN(CC1)c1c(cnc2ccc(F)cc12)C#N		Activator					
ADR000520	VU-6009003	Preclinical	Schizophrenia	C21H19FN4O	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1ccc(OC2CCN(CC2)c2c(cnc3ccc(F)cc23)C#N)cn1	ASD01840206	Activator					
ADR000521	VU-6008848	Preclinical	Schizophrenia	C22H20FN5O3S	Muscarinic acetylcholine receptor M4	ASD01840000_1	NS(=O)(=O)c1ccc(NC(=O)C2CCN(CC2)c2c(cnc3ccc(F)cc23)C#N)cc1	ASD01840322	Activator					
ADR000522	ABI-H2158	Phase I	Hepatitis B (HBV)		Capsid protein	ASD15280000_1			Regulator					
ADR000523	BMT-062552	Preclinical	Psychosis	C20H20ClFN4	Metabotropic glutamate receptor 2	ASD01880000_1	Fc1ccc(cc1)[C@H]1C[C@@H]1CNc1ccn2c(CC3CC3)nnc2c1Cl	ASD01885042	Activator		WO 2013138687			
ADR000524	BMT-080676	Preclinical	Psychosis	C19H15F7N4	Metabotropic glutamate receptor 2	ASD01880000_1	Fc1ccc(cc1)[C@H]1C[C@@H]1CNc1ccn2c(CC(F)(F)F)nnc2c1C(F)(F)F	ASD01885043	Activator		WO 2013138687			
ADR000525	VU-6010572	Preclinical	Depression	C20H18FNO3	Metabotropic glutamate receptor 3	ASD05170000_1	C[C@@H](COC1=CC(=O)N(C=C1)c1ccc(F)cc1)Oc1ccccc1 |c:9,t:4|	ASD05170035	Inhibitor		WO 2016130652			
ADR000526	RTICBM-74	Preclinical	Cocaine dependency	C19H14ClFN2O	Cannabinoid receptor 1	ASD03330000_1	Fc1ccc(cc1)-c1cccc(NC(=O)Nc2ccc(Cl)cc2)c1	ASD03331806	Regulator		WO 2018209030			
ADR000527	VU-6001966	Preclinical	Autism spectrum disorders; Anxiety disorder; Obsessive-compulsive disorder; Depression; Cognitive disorders	C17H15FN4O2	Metabotropic glutamate receptor 2	ASD01880000_1	Cn1ccc(COc2cnc(cc2-c2ccc(F)cc2)C(N)=O)n1	ASD01885044	Inhibitor		WO 2016149324			
ADR000528	VU-6005649	Preclinical	Epilepsy; Anxiety disorder; Depression; Attention deficit hyperactivity disorder (ADHD); Schizophrenia; Cognitive disorders; Autism	C16H12F5N3O	Metabotropic glutamate receptor 7;Metabotropic glutamate receptor 8	ASD01920000_2;ASD05180000_1	COc1ccc(-c2c(C)nn3c(cc(C)nc23)C(F)(F)F)c(F)c1F	ASD01920052	Activator;Activator					
ADR000529	VU-6009454	Preclinical	Schizophrenia; Parkinson's disease; Huntington's disease	C21H19F3N4O	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1cc(C)c2cc(ccc2n1)C(=O)NC1CN(C1)c1ccc(nc1)C(F)(F)F	ASD01840153	Activator		WO 2018112312			
ADR000530	VU-6009453	Preclinical	Schizophrenia; Parkinson's disease; Huntington's disease	C21H21ClN4O2	Muscarinic acetylcholine receptor M4	ASD01840000_1	COc1cc(N2CC(C2)NC(=O)c2ccc3nc(C)cc(C)c3c2)c(Cl)cn1	ASD01840157	Activator		WO 2018112312			
ADR000531	VU-6008541	Preclinical	Schizophrenia; Parkinson's disease; Huntington's disease	C20H18Cl2N4O	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1cc(C)c2cc(ccc2n1)C(=O)NC1CN(C1)c1cc(Cl)ncc1Cl	ASD01840192	Activator		WO 2018112312			
ADR000532	VU-6009548	Preclinical	Schizophrenia; Parkinson's disease; Huntington's disease	C20H18F2N4O	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1cc(C)c2cc(ccc2n1)C(=O)NC1CN(C1)c1ccnc(F)c1F	ASD01840194	Activator		WO 2018112312			
ADR000533		Preclinical	Psychosis	C18H18N4OS	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)N3CC(C3)c3ccccc3)c(N)c2c1C	ASD01840327	Activator		WO 2013126856			
ADR000534		Preclinical	Psychosis	C18H17FN4OS	Muscarinic acetylcholine receptor M4	ASD01840000_1	Cc1nnc2sc(C(=O)N3CC(C3)c3cccc(F)c3)c(N)c2c1C	ASD01840328	Activator		WO 2013126856			
ADR000535	[18F]ER-000604699	Preclinical	Diagnostics; Dementia, Alzheimer's type		Metabotropic glutamate receptor 2;Metabotropic glutamate receptor 3	ASD01880000_1;ASD05170000_1			Inhibitor;Inhibitor					
ADR000536		Preclinical	Anxiety disorder; Hyperalgesia	C20H17N3O4	Gamma-aminobutyric acid type B receptor	ASD01150000_1	COc1ccc2cnc3c(cnn3c2c1)C(=O)OCc1ccccc1OC	ASD01151115	Activator					
ADR000537	VU-6010608	Preclinical	Anxiety disorder	C18H15F3N4O4	Metabotropic glutamate receptor 7	ASD01920000_2	COc1ccc(cc1OC)C(=O)Nc1cc(OC(F)(F)F)ccc1-n1cncn1	ASD01920087	Inhibitor					
ADR000538		Preclinical	Dementia, Alzheimer's type	C26H19FN4O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1cc(cn1)-c1ccc(CN2Cc3cccc(Oc4c(F)cccc4C#N)c3C2=O)cc1	ASD01811934	Activator		WO 2014077401			
ADR000539		Preclinical	Dementia, Alzheimer's type	C25H27N3O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1ccc(n1)-c1ccc(CN2Cc3cccc(O[C@H]4CCCC[C@@H]4O)c3C2=O)cc1	ASD01814729	Activator		WO 2014077401			
ADR000540	PPTQ	Preclinical	Psychiatric Disorders; Cognitive disorders	C21H16N2O	Gamma-aminobutyric acid receptor subunit alpha-4;Gamma-aminobutyric acid receptor subunit beta2;Gamma-aminobutyric acid receptor subunit delta	ASD01140000_14;ASD01140000_2;ASD01140000_11	Cc1ccc(cc1)N1C(=O)c2ccccc2N=C1c1ccccc1 |c:18|	ASD01140469	Activator;Activator;Activator					
ADR000541	RV-I-029	Preclinical	Neuralgia, trigeminal; Migraine; Depression; Attention deficit hyperactivity disorder (ADHD); Schizophrenia; Tinnitus; Huntington's disease; Tic disorder	C18H12D3N3O3	Gamma-aminobutyric acid receptor subunit alpha-6;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_16;ASD01140000_10;ASD01140000_1	[2H]C([2H])([2H])Oc1ccc2C3=NN(C(=O)C3=CNc2c1)c1ccc(OC)cc1 |c:15,t:9|	ASD01140719	Activator;Activator;Activator		WO 2016196961			
ADR000542	DK-I-60-3	Preclinical	Neuralgia, trigeminal; Migraine; Depression; Attention deficit hyperactivity disorder (ADHD); Schizophrenia; Tinnitus; Huntington's disease; Tic disorder	C18H9D6N3O3	Gamma-aminobutyric acid receptor subunit alpha-6;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2	ASD01140000_16;ASD01140000_10;ASD01140000_1	[2H]C([2H])([2H])Oc1ccc(cc1)N1N=C2C(=CNc3cc(OC([2H])([2H])[2H])ccc23)C1=O |c:13,15|	ASD01140722	Activator;Activator;Activator		WO 2016196961			
ADR000543	PZ-II-029	Preclinical	Psychiatric Disorders	C18H15N3O3	Gamma-aminobutyric acid receptor subunit alpha-1;Gamma-aminobutyric acid receptor subunit beta3;Gamma-aminobutyric acid receptor subunit gamma2;Gamma-aminobutyric acid receptor subunit alpha6	ASD01140000_3;ASD01140000_10;ASD01140000_1;ASD01140000_16	COc1ccc(cc1)N1N=C2C(=CNc3cc(OC)ccc23)C1=O |c:10,12|	ASD01140527	Activator;Activator;Activator;Activator					
ADR000544	(R)-VU-0488129; VU-0488129	Preclinical	Stroke, ischemic; Dementia, Alzheimer's type	C24H28N4O3S	Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M5	ASD01830000_1;ASD01810000_1;ASD01850000_1	CCN([C@@H]1CCc2ccccc12)C(=O)C1CCN(CC1)S(=O)(=O)c1ccc2[nH]ncc2c1	ASD01814739	Activator;Activator;Activator					
ADR000545	VU-6007475	Preclinical	Schizophrenia; Cognitive disorders	C25H28N6O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1cc(cn1)-c1ccc(Cc2cc(nc3n(C)ccc23)C(=O)N[C@H]2CCCC[C@@H]2O)cn1	ASD01814744	Activator		WO 2018063552			
ADR000546	VU-6007477	Preclinical	Schizophrenia; Cognitive disorders	C24H26N6O2	Muscarinic acetylcholine receptor M1	ASD01810000_1	Cn1cc(cn1)-c1ccc(Cc2cc(nc3n(C)ccc23)C(=O)NC2CCOCC2)cn1	ASD01814790	Activator		WO 2018063552			
ADR000547		Preclinical	Pain		Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	Br[H].CC(C)[C@H](N)C(=O)NC(C(C)C)C(=O)Oc1ccc(CCC(=O)c2cc(O)ccc2O)cc1		Inhibitor					
ADR000548		Preclinical	Pain		Neuronal acetylcholine receptor subunit alpha-7	ASD03090000_1	Br[H].CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NC(C(C)C)C(=O)Oc1ccc(CCC(=O)c2cc(O)ccc2O)cc1		Inhibitor					
ADR000549	(R)-VU-6007678; VU-6007678	Preclinical	Stroke, ischemic; Dementia, Alzheimer's type	C25H29FN4O3S	Muscarinic acetylcholine receptor M3;Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M5	ASD01830000_1;ASD01810000_1;ASD01850000_1	CCCN([C@@H]1CCc2c1cccc2F)C(=O)C1CCN(CC1)S(=O)(=O)c1ccc2[nH]ncc2c1	ASD01814806	Activator;Activator;Activator					
ADR000550	21-Hydroxyganaxolone	Preclinical	Epilepsy	C22H36O3	Gamma-aminobutyric acid-A receptor	ASD01140000_1	[H][C@@]12CC[C@H](C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C	ASD01140732	Activator					
ADR000551	ABM-300	Preclinical	Bipolar disorder; Schizophrenia		Cannabinoid receptor 1	ASD03330000_1			Inhibitor					
ADR000552	CAD-8688	Preclinical	Schizophrenia		Glutamate receptor ionotropic, NMDA 2A	ASD02030000_4			Activator					
ADR000553	AC-0026669	Preclinical	Pain; Arthritis		High affinity nerve growth factor receptor	ASD07480000_1			Inhibitor					
ADR000554	[11C]mG-2P001	Preclinical	Diagnostics		Metabotropic glutamate receptor 2	ASD01880000_1	Cn1c(CN2CCC(CC2)c2ccc(cc2O[11CH3])C(F)(F)F)nc2ncccc12		Activator					
ADR000555	VU-0486846	Preclinical	Cognitive disorders	C25H28N4O3	Muscarinic acetylcholine receptor M1	ASD01810000_1	O[C@H]1CCCC[C@@H]1NC(=O)[C@H]1CN(Cc2ccc(cc2)-n2cccn2)c2ccccc2O1	ASD01812450	Activator		WO 2015080904			
ADR000556	AP-5	Preclinical	Diabetes type 2	C28H27FNNaO4	Free fatty acid receptor 1	ASD09380000_1	[Na+].COc1cc(ccn1)-c1ccc([C@@H]2CCc3ccc(cc3O2)[C@@H]([C@H](C)C([O-])=O)C2CC2)c(F)c1	ASD09380018	Activator		WO 2014130608			
ADR000557		Preclinical	Parkinson's disease	C17H16N6	Metabotropic glutamate receptor 4	ASD01900000_1	Cn1nc(C2CC2)c2ccc(Nc3n[nH]c4cccnc34)cc12	ASD01901622	Activator		WO 2016123629			
ADR000558	KRM-II-82	Preclinical	Epilepsy; Anxiety disorder	C22H14N4O	Gamma-aminobutyric acid receptor subunit alpha-3	ASD01140000_13	C#Cc1ccc-2c(c1)C(=NCc1c(ncn-21)-c1cnco1)c1ccccc1 |c:9|	ASD01140741	Activator		WO 2016154031			
ADR000559	MP-III-080	Preclinical	Epilepsy; Anxiety disorder	C22H16N6O	Gamma-aminobutyric acid receptor subunit alpha-3	ASD01140000_13	CCc1noc(n1)-c1ncn-2c1CN=C(c1ccccn1)c1cc(ccc-21)C#C |t:15|	ASD01140328	Activator		US 2010261711; WO 2003082832; WO 2017161370			
ADR000560		Preclinical	Diabetes type 2	C27H28ClN3O4	Free fatty acid receptor 1	ASD09380000_1	COc1cc(c(Cl)cn1)-c1cnc([C@@H]2CCc3ccc(cc3O2)[C@@H]([C@H](C)C(O)=O)C2CC2)c(C)n1 |r|	ASD09380020	Activator		WO 2014130608			
ADR000561	EAI-045	Preclinical	Cancer	C19H14FN3O3S	Epidermal growth factor receptor	ASD01020000_1	Oc1ccc(F)cc1C(N1Cc2ccccc2C1=O)C(=O)Nc1nccs1	ASD01020010	Inhibitor		CN 108191849			
ADR000562	SUVN-I2004	Preclinical	Dementia, Alzheimer's type		Muscarinic acetylcholine receptor M1	ASD01810000_1			Activator					
ADR000563	MDL-800	Preclinical	Cancer	C21H16BrCl2FN2O6S2	NAD-dependent protein deacetylase sirtuin-6	ASD14460000_1	COC(=O)c1cc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)ccc1S(=O)(=O)Nc1cc(Br)c(F)cc1C	ASD14460002	Activator					
